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  1 
I. INTRODUCTION 
1.1 The Immune System 
There are two major components of the immune system known as the innate immune system 
and adaptive immune system. The innate immune system arose early in evolution and is the 
dominant host defense found in most organisms (Litman et al., 2005). It is characterized as 
being non-specific, generates a quick response and has the same intensity in the second 
response, there is no immunological memory, and involves soluble proteins (complement 
proteins, acute phase proteins, cytokines and chemokines) as well as cells including 
monocytes/macrophages, dendritic cells, granulocytes, natural killer (NK) cells, and mast 
cells. The innate system is intricately associated with the adaptive immune system since these 
soluble proteins and cells are essential for activating and participating in an adaptive immune 
response.  
The adaptive immune system evolved later in early vertebrates (Pancer and Cooper, 2006). In 
contrast to the innate immune system, it is specific, there is a lag time between exposure and 
maximal response, immunological memory is generated, and the lymphocytes are integral to 
the adaptive immune response. The lymphocytes include T and B cells, which can be 
activated through membrane-bound receptors. The diversity of these antigen-specific 
receptors arises from their generation by random recombination of variable receptor gene 
segments and the pairing of different variable chains (Janeway et al., 1999). Upon recognition 
of a foreign antigen, B and T cells undergo clonal expansion over the period of a few days 
accounting for the time lag. Some of these cells differentiate into plasma and memory cells, 
which can respond rapidly to another encounter of the foreign antigen.  
The B cells recognize foreign antigens with a membrane-bound immunoglobulin while T cells 
recognize peptides generated from antigens bound to major histocompatibility molecules 
(MHC) with the T cell receptor. The T cell receptor is restricted in the sense that it can only 
recognize a unique combination of a specific foreign peptide antigen bound to a particular 
MHC molecule (Stevanovic, 2002).  
 
1.2 Major Histocompatibility Complex Molecules 
The major histocompatibility complex contains over 200 genes encoding for highly 
polymorphic proteins involved in antigen processing and presentation as well as complement 
proteins, cytokines, enzymes, and other proteins whose functions have not yet been ascribed 
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(Janeway et al., 1999). The polygeny and polymorphism of MHC molecules increases the 
ability of the immune system to combat pathogens by extending the range of peptides that can 
be bound, but also poses a challenge in the fields of autoimmunity and transplantation.  
The two classes of major histocompatibility complex molecules, MHC-I and MHC-II, differ 
from each other in terms of structure, function, and activation of T cells. MHC-I molecules 
are comprised of the human leukocyte antigens (HLA) A, B, and C in humans and H-2K, H-
2D, and H-2L in mice. MHC-I is expressed on all nucleated cells and thrombocytes. MHC-I 
contains one cytoplasm-spanning domain, α3, two other domains serving as the peptide-
binding cleft, α1 and α2, and a non-covalently associated chain, β2-microglobulin. These 
molecules bind peptides from proteins degraded in the cytoplasm and present the peptides to 
CD8+ cytotoxic T cells. The peptides are generally degraded proteins ranging from 8-10 
amino acids originating from viruses and intracellular pathogens. The cytotoxic cells have an 
immediate, direct effect of killing the cells displaying these antigens thus reducing the number 
of cells infected with pathogens (Janeway et al., 1999). 
Major histocompatibility complex class II molecules include HLA-DR, HLA-DP, and HLA-
DQ in humans and I-A and I-E in mice. They are polymorphic transmembrane heterodimers 
formed by the non-covalent association of a 34 kD α-chain and a 29 kD β-chain. They are 
constitutively expressed on B lymphocytes, dendritic cells, and macrophages, which are 
known as antigen presenting cells (APC). However, MHC-II expression can also be induced 
on other cell types, usually due to induction by interferon-γ. MHC-II molecules also have four 
domains including two cytoplasm-spanning domains, α2 and β2, and the α1 and β1 domains, 
which serve as the peptide-binding cleft. The peptides can be larger in size since the ends of 
the peptide-binding cleft are more open. The peptides are usually captured after protein 
degradation in endocytic vesicles or after internalization of antigens bound to 
immunoglobulin receptors of B cells. These peptides usually stem from intravesicular bacteria 
and parasites and are presented to CD4+ helper T cells. The CD4+ helper T cells operate 
indirectly by activating other effector cells of the immune system such as macrophages or B 
cells, which then proceed in clearing the site from foreign molecules (Janeway et al., 1999).   
 
1.3 Major Histocompatibility Complex Class II Signaling 
One of the most important functions of MHC-II molecules is the presentation of peptides to 
helper T cells. However, research over the past 20 years indicates that MHC-II molecules also 
play a role in signal transduction. With the help of monoclonal antibodies, superantigens, and 
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the lymphocyte-activating gene-3 (LAG-3) protein as ligands, MHC-II molecules have been 
linked to a variety of signaling pathways. These signaling pathways include protein tyrosine 
kinases (PTKs), which are associated with various cellular responses including cytokine 
production, homotypic aggregation, and  proliferation/differentiation, protein kinase C (PKC), 
which has been linked to apoptosis and organization of the cytoskeleton, and mitogen-
activated protein kinases (MAPK), which are also important in cell 
proliferation/differentiation (Charron et al., 1991; Mooney, et al., 1990; Kansas and Tedder, 
1991; Bertho et al., 2002; Castaigne et al., 2002; Guo et al., 2003; Partida-Sanchez et al., 
2002; Leveille et al., 2002; Matsuoka et al., 2001). 
The protein tyrosine kinases are one of the first groups of signaling molecules activated upon 
MHC-II ligation. This group is composed of over 90 members, and they are classified 
according to their cytoplasmic localization or their ability to associate with receptors (RTK). 
Within 15 seconds of MHC-II ligation, intracellular tyrosine phosphorylation can be observed 
(Al-Daccak et al., 1994). MHC-II ligation leads to tyrosine kinase-dependent rapid homotypic 
adhesion mediated by LFA-1/ICAM interactions and other unidentified adhesion molecules 
(Kansas and Tedder, 1991). PTK inhibitors such as genistein and herbimycin were able to 
inhibit B cell aggregation induced by anti-MHC-II antibodies (Fuleihan et al., 1992; Mourad 
et al., 1990). While the Src family of tyrosine kinases may be relevant for MHC-II-mediated 
cytokine production, syk has been shown to be important for MHC-II-induced dendritic cell 
maturation (Kühn et al., 1998; Scholl and Geha, 1994; Andreae et al., 2003).  
Downstream events of protein tyrosine kinase activation include the activation of 
phospholipase C-γ (PLC-γ), which is required for calcium mobilization. Phospholipase C-γ 
cleaves phosphatidylinositol bisphosphate (PIP2) into inositol triphosphate (IP3) and 
diacylglycerol (DAG). IP3 binds to receptors expressed on the endoplasmic reticulum 
triggering the release of sequestered calcium into the cytosol. Calcium channels in the plasma 
membrane are then activated, allowing for an additional increase in intracellular calcium 
levels. Not only are PLCγ2 and p72syk phosphorylated after LAG-3 ligation on human 
immature dendritic cells, but PLCγ1 is also activated after cross-linking MHC-II molecules 
expressed on activated human T cells (Andreae et al., 2003; Kanner et al., 1992). 
Phosphatidyl inositol turnover and calcium flux have also been measured in B cells after 
MHC-II ligation (Lane et al., 1990). In addition, calcium mobilization was recently described 
as a MHC-II non-haplotype-specific event in resting murine B lymphocytes (Nashar and 
Drake, 2006). 
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Another kinase that is often linked to MHC-II signal transduction, but remains ambiguous in 
terms of its actual function in MHC-II signaling, is protein kinase C. PKC has been divided 
up into several subfamilies based on their second messenger requirements. Conventional 
PKCs including α, βI, βII, and γ require calcium, diacylglycerol, and a phospholipid for 
activation. Novel PKCs including δ, ε, η, and θ require DAG, but not calcium for activation. 
Atypical PKCs including λ and ι do not require DAG nor calcium. One of the first reports on 
transmembrane signaling through MHC class II molecules describes PKC being translocated 
to the nucleus, which differs from BCR-mediated translocation of PKC to the plasma 
membrane (Chen et al., 1987). MHC-II-derived signaling has also revealed the translocation 
of PKCδ into the nucleus upon activation in mature dendritic cells, and the conventional PKC, 
PKCβ, is activated in a Src-independent manner in monocytes and B cells (Bertho et al., 
2002; Castaigne et al., 2002; Guo et al., 2003). These studies have also shown that inhibition 
of PKC abrogates MHC-II-mediated apoptosis and that PTK do not affect apoptosis. 
Translocation of PKCα and -βII has also been described, although only PKCδ has been 
described as an isoenzyme with pro-apoptotic properties (Garban et al., 1998; Rich et al., 
1997; Ghayur et al., 1996). Experimental evidence demonstrating the involvement of PKCδ in 
apoptosis has been shown with the overexpression of the cleaved 40 kDa catalytic fragment of 
PKCδ, which induced the appearance of apoptotic morphology, and phorbol ester stimulation 
caused mitochondrial translocation of PKCδ and ensuing apoptosis using a cytochrome c-
release pathway (Ghayur et al., 1996; Majumder et al., 2000). 
Another group of kinases that has recently been associated with MHC-II signaling is the 
mitogen-activated protein kinases (MAPKs). MAPKs have been classified into six different 
groups including extracellular signal-regulated 1/2 (ERK1/2) kinases or classical MAP 
kinases, which are usually activated by growth factors and phorbol ester and lead to the 
regulation of cell proliferation and differentiation, c-Jun N-terminal kinases (JNKs), which 
are also known as stress-activated protein kinases (SAPKs), p38 makes up another group that 
is similarly activated by stress stimuli including cytokines, ultraviolet irradiation, heat shock 
and osmotic shock and are important in cell differentiation and apoptosis, ERK5 is also 
activated by growth factors and stress stimuli and plays a role in cell proliferation, and 
ERK7/8, which is a newly characterized group that displays similarities to ERK5 
(Bogoyevitch and Court, 2004). Interestingly, in MHC-II signaling the MAP kinases appear 
to be activated in an isotype-specific manner. For example, HLA-DP but not HLA-DR 
activates ERK1/2 in B cells, whereas HLA-DR-restricted T cells stimulate monocytes to 
produce IL-1β in a partially p38- and ERK1/2-dependent manner, but HLA-DP/HLA-DQ-
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restricted T cells stimulate the production of IL-10 in a p38-dependent manner (Leveille et al., 
2002; Matsuoka et al., 2001). Fibroblasts can also express HLA-DR after stimulation with 
IFN-γ, and here it was shown that the MHC-II-mediated induction of the chemokine 
RANTES is JNK-2-dependent, but not Src-dependent (Meguro et al., 2003). Thus it appears 
that different MAP kinase pathways can be activated through MHC-II signaling, but the types 
of MAP kinases that are activated varies according to MHC-II isotype and type of cell 
expressing MHC-II (Leveille et al., 2002; Matsuoka et al., 2001).   
 
1.4 Superantigens Trigger MHC-II Signaling 
In addition to monoclonal antibodies and LAG-3, superantigens are a useful tool for 
activating MHC-II signaling pathways. Superantigens are toxins produced from microbes and 
viruses such as Staphylococcus, Streptococcus, Mycoplasma, Yersinia, and the mouse 
mammary tumor virus (MMTV). These toxins are globular proteins ranging between 22-29 
kDa and display several characteristics including resistance to proteases and heat denaturation 
as well as being readily absorbed by the endothelium (Papargeorgiou and Acharya, 2000; 
Hamad et al., 1997). The name ‘superantigen’ is derived from their ability to activate T cells 
oligoclonally (White et al., 1989). Superantigens can activate up to 20 % of T cells, which 
contrasts sharply with conventional peptide antigens that can only stimulate 0.001-0.0001 % 
T cells (Fraser et al., 2000). Not only does their potency separate superantigens from antigens, 
but superantigens are also not phagocytosed and processed into small peptides by antigen 
presenting cells nor are they displayed on major histocompatibility complex class II 
molecules by conventional means. Superantigens bind outside the MHC-II peptide-binding 
groove, and this superantigen-MHC-II complex is recognized by certain subsets of T cells 
bearing specific T cell receptor-variable β chains (TCR-Vβ). While activation and 
proliferation of T cells leads to the most devastating effects of superantigen-induced disease 
including the release of massive amounts of cytokines contributing to the clinical symptoms 
associated with food poisoning, acute shock, and scarlet fever, antigen presenting cells also 
become activated when superantigens bind (Manders, 1998; Wieneke et al., 1999; Fraser et 
al., 2000). Peripheral blood monocytes have been shown to produce IL-1 and TNF-α upon 
MHC-II interaction with superantigen (Trede et al., 1991). This has led to questions 
concerning the signaling mechanism/s triggered after superantigen binding to MHC-II 
molecules.  
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Superantigens have different modes of binding to MHC-II molecules including superantigens 
that can bind to single MHC-II α chains (e.g. staphylococcal enterotoxin B (SEB) and toxin 
shock syndrome toxin-1 (TSST-1)), some bind to single MHC-II β chains in a zinc ion-
dependent manner (streptococcal pyrogenic exotoxin-C (SPE-C) and staphyloccal enterotoxin 
H (SEH)), and some superantigens can bind to two MHC-II α chains, two MHC-II β chains, 
or a combination of MHC-II α and β chains. By cross-linking MHC-II molecules with 
superantigens such as staphylococcal enterotoxin A (SEA) and Mycoplasma arthriditis-
derived superantigen (MAS), various cellular events such as the synthesis of proinflammatory 
cytokines can occur (Homfeld et al., 1990; Rink et al., 1992, 1994; Rink and Kircher, 1992; 
Al-Daccak et al., 1994; Mehindate et al., 1995; Tiedemann and Fraser, 1996; Bernatchez et 
al., 1997). For example, MAS stimulation of murine bone marrow-derived macrophages led 
to the release of IL-6, and TNF-α secretion was observed in murine and human leukocytes 
(Homfeld et al., 1990; Rink et al., 1994).  
 
1.5 Apoptosis Mediated by MHC-II Molecules 
Apoptosis, or programmed cell death, allows the elimination of cells in a controlled manner. 
Apoptosis can be triggered through external factors that lead to DNA damage such as 
cytotoxic drugs and ultraviolet and x-irradiation, by loss of cell contact with its surroundings, 
or through activation of cell surface receptors (Nagy and Mooney, 2003). Apoptosis is an 
important process as improper functioning can lead to malignancies or autoimmune disease. 
Classical apoptosis requires the proteolytic cleavage of cysteine aspartic acid proteases or 
caspases, which eventually leads to disintegration of the cell. However, caspase-independent 
forms of apoptosis have been described after signaling through different cell surface receptors 
such as CD2, CD20, and CD45 (Déas et al, 1998; Chan et al., 2003; Lesage et al, 1997).    
MHC-II-mediated apoptosis is insensitive to caspase inhibitors such as DEVD-fmk, which 
inhibits caspase-3, and the pan caspase inhibitor zVAD-fmk (Drénou et al., 1999). Cleavage 
of the nuclear enzyme poly(ADP-ribose) polymerase does not occur, which is another 
hallmark of caspase-mediated apoptosis (Drénou et al., 1999). Unlike other forms of 
apoptosis, MHC-II-induced apoptosis is extremely rapid and cells deteriorate quickly where it 
can be completed between 30 minutes to 4 hours depending on the cell line (Nagy et al., 
2002). Physical characteristics of apoptosis mediated by MHC-II include the exposure of 
phosphatidyl-serine to the outer surface of the cell, membrane blebbing, and minor chromatin 
condensation (Truman et al., 1994).   
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As in other forms of apoptosis, the mitochondria are also affected during MHC-II-mediated 
apoptosis and the release of apoptogenic proteins help in the demise of the cell. Marked 
swelling of the mitochondria can be seen within 30 minutes of MHC-II ligation and 
mitochondrial membrane potential is reduced (Nagy and Mooney, 2003; Bertho et al., 2002). 
As mentioned previously, the exact mechanism behind MHC-II-induced cell death has not 
been fully elucidated, but appears to involve PKC (see 1.3).  
Interestingly, ligation of MHC-II molecules on mature dendritic cells and on activated or 
differentiated monocytes/macrophages induces apoptosis, but not in immature dendritic cells 
and primary monocytes (Bertho et al, 2002; Castaigne et al., 2002). Since mature dendritic 
cells and monocytes are relatively resistant to the Fas death pathway, this may indicate that 
MHC-II-mediated apoptosis clears potentially problematic activated cells that cannot be 
removed by the Fas death pathway (Al-Daccak et al., 2004).      
 
1.6 Transcription Factors Involved in MHC-II Signaling 
Gene transcription is regulated by sequence-specific DNA binding proteins known as 
transcription factors. Multiple signaling pathways are integrated in the cell and dictate the 
assembly of a DNA-bound complex containing transcription factors. Transcription factors are 
involved in many cellular processes and are responsible for basal transcription regulation, 
differentiation, response to external stimuli, and cell cycle control. Transcription factors are 
central regulators of immune responses, and their activity is crucial for understanding 
processes ranging from lymphocyte survival to chronic inflammatory diseases. While over 
2600 DNA binding proteins are known to exist with most of them acting as transcription 
factors, only three will be discussed in detail in this work: NF-κB, NFAT, and AP-1 (Babu et 
al., 2004).    
Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) is named after 
Baltimore’s discovery of enhancer proteins interacting with an 11-base pair sequence of the 
immunoglobulin light chain enhancer in B cells (Sen and Baltimore, 1986). Due to the 
homology of the N-terminus of NF-κB with the retroviral oncoprotein v-Rel, NF-κB has been 
classified in the Rel proteins. There are five different mammalian NF-κB proteins including 
p105 and p100, which are later processed into the NF-κB subunits p50 and p52, respectively, 
and RelA, RelB, and c-Rel make up the other NF-κB proteins (Nabel and Verma, 1993). 
Inactive NF-κB is normally sequestered in the cyotoplasm by inhibitor proteins (IκB), which 
masks the nuclear localization signal (NLS). Upon signal transduction by receptors such as 
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Toll-like receptors, B cell receptor, or T cell receptor, the inhibitor proteins are 
phosphorlyated by kinases, in particular IκB, which ultimately leads to their ubiquitination 
and degradation by a proteasome. The nuclear localization signal is then exposed allowing for 
transport of NF-κB into the nucleus and subsequent transcription of genes involved in cellular 
differentiation and proliferation.  
Similar to NF-κB, nuclear factor of activated T cells (NFAT) is a misnomer since this 
transcription factor can be found in cells other than the name implies. NFAT is expressed in 
many different cells within the immune system (B lymphocytes, NK cells, macrophages, mast 
cells, eosinophils, among others), in skeletal and cardiac muscle, and the nervous system 
(Yaseen et al., 1993; Aramburu et al., 1995; Hutchinson and McCloskey, 1995; Ho et al., 
1994). Four different calcium regulated members have been identified, NFAT1-NFAT4, 
whereas the recently discovered NFAT5 is activated independently of calcium. NFAT1-
NFAT4 relies on calcium signaling to trigger the calcium sensor protein calmodulin in 
allowing calcineurin to dephosphorylate NFAT, which leads to a conformational change and 
exposure of the NLS for nuclear import. Engagement of receptors such as the B cell receptor, 
T cell receptor, Fcγ receptor of macrophages and NK cells, and Fcε receptor of mast cells and 
basophils can lead to rises in intracellular calcium and then activation of NFAT. NFAT is 
involved in a variety of cellular processes including neural development and axon growth, 
osteoclast formation, cytokine production, and peripheral tolerance. The weak binding 
capacity of NFAT to DNA often requires the presence of other transcription factors including 
AP-1. 
Activator protein 1 (AP-1) is a transcription factor composed of dimeric basic region-leucine 
zipper (bZIP) proteins that belong to the Jun, Fos, Maf, and ATF sub-families. While NFAT 
relies on calcium signaling, AP-1 is activated through signaling pathways that include PKC, 
the small G protein Ras, and several MAP kinases including ERK and JNK. Growth factors, 
cytokines, neurotransmitters, polypeptide hormones, bacterial and viral infections, and 
different physical and chemical stress factors trigger the activation of AP-1. Pro-inflammatory 
cytokines and stress initiate JNK and p38 cascades, which lead to AP-1 induction. AP-1 
activity can be enhanced by the classical group of MAP kinases where they can encourage 
ternary complex factors (TCFs) to bind to fos promoters (Shaulian and Karin, 2002). AP-1 
can either positively or negatively regulate cell proliferation by affecting genes involved in 
cell cycle progression and apoptosis such as p53, cyclin D1, and Fas/FasL (Shaulian and 
Karin, 2001; Schreiber et al., 1999; Ivanov et al., 2001).  
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1.7 Associated Molecules Involved in MHC-II Signaling 
The lack of known signaling motifs in the short cytoplasmic tail of MHC II molecules poses 
the question of how signals emanating from MHC-II molecules can be transduced into the 
cell. For this task, many molecules found associated with MHC-II have been identified and 
reported as important for MHC-II-mediated signal transduction. The list of associated 
molecules varies according to cell type. For example, CD19, CD20, CD79a/CD79b, and 
CD81 expressed on B cells have been shown to be associated with MHC-II on a molecular 
level and/or functional level (Leveille et al., 2002; Boucheix and Rubinstein, 2001; Mills et 
al., 2004; Jin et al., 2008a). However, since the majority of these molecules make up the B 
cell receptor or B cell coreceptors, other antigen presenting cells such as dendritic cells and 
monocytes require other molecules to aid in transducing MHC-II-initiated signals. On 
monocytes, a viable candidate would be the β2-integrin CD18, which can associate with 
HLA-DR and aid in activating either Src kinases or PKCβ depending on whether or not this 
complex is found inside or outside lipid rafts.  
Lipid rafts are cholesterol-dependent glycolipid-enriched membrane microdomains (GEMS), 
which are increasingly being discussed for their involvement in immune cell receptor 
signaling. The immunological synapse, which is the site of interaction between T 
lymphocytes and APC, harbors many signaling proteins localized in lipid rafts. The interest of 
immunologists in lipid rafts started with the glycosylphosphatidylinositol (GPI) lipid 
anchored proteins including Thy-1, which can activate immune cells even though the anchor 
does not extend through the lipid bilayer (Stefanova et al., 1991). Immunoprecipitation 
studies uncovered that Thy-1 associates with the Src family tyrosine kinase Lck, and after this 
discovery, many different molecules that localize to lipid rafts after activation were also found 
to associate with tyrosine kinases, including MHC-II molecules (Stefanova et al., 1991; Shaw, 
2006; Huby et al., 1999). By disrupting lipid rafts with methyl-β-cyclodextrin, tyrosine 
kinases could no longer be activated after ligating MHC-II molecules on the IFN-γ-stimulated 
monocytic cell line, THP-1 (Huby et al., 1999). Other components of the MHC-II-mediated 
signaling pathways were still functional after lipid raft disruption, including the activation of 
PKCβ leading to cell death and the phosphorylation of the MAP kinase, ERK1/2 (Bouillon et 
al., 2003; Doisne et al., 2008). Therefore, intact lipid rafts are only partly linked to MHC-II 
signaling. 
Another group of proteins implicated in MHC-II signaling is the tetraspanins. Tetraspanins 
modulate intercellular immune interactions such as adhesion, migration, and synapse 
formation and help organize membrane-signaling complexes (Levy and Shoham, 2005). 
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Tetraspanins are organized in membrane microdomains that may not correspond with lipid 
rafts (Hemler et al., 2003; Rubinstein et al., 1996). The tetraspanin CD9 forms a complex with 
CD38 and MHC-II on human monocytes, and all three molecules share a common activation 
pathway involving the tyrosine kinases Fgr and Hck (Zilber et al., 2005). A novel tetraspanner 
known as MPYS was also recently discovered and has been linked to MHC-II-mediated 
apoptosis in murine B cells (Jin et al., 2008b). Altogether, MHC-II relies on different 
signaling receptors, tetraspanins, and lipid rafts to propagate signals into the cell (Fig. 1.1). 
 
 
 
Figure 1.1 – MHC-II-mediated Signaling Pathways. MHC-II requires other signaling partners and 
intact lipid rafts for the transduction of signals. While the activation of tyrosine kinases and 
mobilization of calcium require intact lipid rafts, the classical MAP kinases are activated outside lipid 
rafts.  This shows a model based on publications describing the major MHC-II pathways (Al-Daccak, 
et al., 2004; Leveille et al., 2002) 
 
1.8 Immunoglobulin Synthesis 
One of the major contributions of B lymphocytes to the immune response is the secretion of 
antibodies, which are important for the neutralization and opsonization of pathogens as well 
as activation of the complement system. Antibody production can be initiated by two different 
mechanisms in B lymphocytes. The first of these mechanisms involves protein antigens, 
which can only trigger antibody synthesis from B cells with the help of T cells, and these 
antigens are known as thymus-dependent (TD) antigens. By peptide presentation on MHC 
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molecules expressed by B cells, helper T cells recognize the peptide:MHC complex with the 
T cell receptor (TCR), and this induces expression of CD40L on T cells, which can bind to 
CD40 on the B cells. Adhesion molecules surrounding the CD40/CD40L and MHC/TCR 
interactions seal this area and reorganize cytoskeletal proteins to allow for cytokine release 
(e.g. IL-4) from the T cell at the point of contact (Janeway et al., 1999). CD40 and cytokines 
that induce transcription from the switch regions of different heavy chain C genes are required 
for isotype switching.  
Another form of activating B cell immunoglobulin synthesis involves certain microbial 
components such as bacterial polysaccharides. Bacterial polysaccharides either have the 
intrinsic ability to activate B cells so that the B cells no longer require the help of T cells 
(thymus-independent class 1 antigens or TI-1) or the highly repetitive structure of the 
polysaccharide can cross-link immunoglobulins on the surface of mature B cells triggering the 
production of antibodies (thymus-independent class 2 antigens or TI-2) (Janeway et al., 
1999).  Thymus-independent antigens induce limited isotype switching and cannot initiate the 
further differentiation of B cells into memory B cells.    
A typical mitogen used to induce immunoglobulin synthesis is pokeweed mitogen (PWM) 
derived from the plant seed Phytolacca americana. Pokeweed mitogen is a T cell and B cell 
mitogen that induces the proliferation and differentiation of B cells with the help of T cells 
and monocytes (Waldmann and Broder, 1982). The effects of superantigens and anti-MHC-II 
antibodies on immunoglobulin synthesis have been explored in PWM-stimulated peripheral 
blood mononuclear cells as well as purified B cells (Stohl et al., 1994; Moseley and Huston, 
1991; Palacios et al., 1983). An increase in antibody production has been reported using high 
concentrations of superantigens, whereas low concentrations of superantigens inhibit antibody 
production (Stohl and Elliott, 1995). HLA-DR ligation has been shown to enhance expression 
of IgM heavy chain genes and replace the role of T helper cells in activating B lymphocytes 
(Tabata et al., 2000; Palacios et al., 1983). However, the mechanisms involved in driving or 
inhibiting immunoglobulin synthesis remain unclear.    
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II. AIM OF THE STUDY 
Although MHC-II molecules are well-known for their ability to present antigens to helper T 
cells, MHC-II molecules can also contribute to signaling pathways that govern the function 
and survival of antigen presenting cells (APC). The concept of MHC-II-induced signaling is 
only approximately 20 years old, and it remains apparent that not all signaling pathways 
linked to MHC-II molecules have been identified. The major goal of this work is to further 
characterize the signaling pathways initiated by MHC-II ligation. MHC-II molecules are 
expressed on a wide range of immune cells including monocytes/macrophages and dendritic 
cells, but this study places an emphasis on B lymphocytes. MHC-II molecules can be broken 
down into three different isotypes, HLA-DR, -DP, and –DQ, and all of these isotypes will be 
examined for their ability to induce different signaling pathways. 
The different signal transduction pathways and components that will be addressed include 
calcium mobilization, dephosphorylation and activation of the transcription factor NFAT, 
activation of the classical MAP kinases, c-Fos protein levels, and AP-1 dimer formation. Two 
forms of ligands will be used to crosslink MHC-II molecules and these include superantigens 
and anti-MHC-II antibodies. Both methods of ligation will be examined for their similarities 
and/or differences in activating the signaling pathways. In addition to exploring the 
importance of isotypes in triggering these signaling pathways, the influence these signaling 
pathways have on cellular responses such as apoptosis will also be addressed. An interesting 
aspect that will also be considered is the effect of MHC-II signaling on the activation of 
NFAT and how this coordinates with B cell receptor signaling. The major function of B 
lymphocytes is the production of antibodies to help stop and prevent the spread of infections, 
and the influence of MHC-II-derived signaling will also be analyzed during this important 
process.  
By exploring the pathways and functional responses mediated by MHC-II molecules, a more 
detailed picture can be gained of antigen presenting cells and what mechanisms are involved 
for their proliferation, differentiation, and elimination. Understanding the role of MHC-II 
molecules in inducing apoptosis has already provided a new therapeutic tool for combating 
lymphomas. This dissertation should widen our perspective on MHC-II-mediated signaling by 
not only extending our knowledge on this topic, but by also giving new insight into regulating 
immune responses, thereby posing possible solutions for the prevention of autoimmune 
diseases and transplant rejection.    
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III. MATERIALS AND METHODS 
3.1 Materials 
3.1.1 Equipment 
• Analytical scales, 770/GS/GJ (Kern, Balingen-Frommern) 
• Bacteria incubator, BE 400 (Memmert, Schwabach) 
• Bacteria shaker, ES-20 (Lab4You, Berlin) 
• Bacteria shaker, IOC 400.XX2.C (Sanyo Gallenkamp, Loughborough, UK) 
• Blot transfer chamber, Mini-trans (Bio-Rad, München) 
• CO2 incubator, MCO-17AIC (Sanyo, Gunma, Japan) 
• Electrophoresis chamber for polyacrylamide gels, Mini-Protean 3 Electrophoresis 
Module Assembly (Bio-Rad, München) 
• Electrophoresis chamber for polyacrylamide gels, Protean II xi (Bio-Rad, München) 
• Electrophoresis net, EPS 3500 XL (Amersham Pharmacia Biotech, Uppsala, Sweden)  
• Electrophoresis power supply, Power Pac 300 (Bio-Rad, München) 
• Electrophoresis power supply, Power Pac 1000 (Bio-Rad, München) 
• Electrophoresis thermostatic circulator, MultiTemp III (Amersham Pharmacia 
Biotech, Uppsala, Sweden) 
• Electrophoresis unit for polyacrylamide gels, Multiphor II (Amersham Pharmacia 
Biotech, Uppsala, Sweden) 
• ELISA Reader, Magellan (Tecan, Crailsheim) 
• ELISA Washer, Atlantis (Asys Hitech, Eugendorf) 
• Flow cytometer, FACScan and FACSCalibur (Becton Dickinson, Heidelberg) 
• Floor centrifuge, Varifuge 3.0 RS (Heraeus Christ, Osterode) 
• Floor centrifuge, Z 400 K (Hermle, Wehingen) 
• Freezer, -20°C (Bosch, München) 
• Freezer, -80°C, MDF-U71V (Sanyo, Gunma, Japan) 
• Geiger counter (Berthold, Bad Wildbad) 
• Gel dryer, Pherotemp (Biotec Fischer, Reiskirchen) 
• Heat sealer, Polystar 100 (Rische and Herfurth, Hamburg) 
• Laboratory scales, 1265 MP (Sartorius, Göttingen) 
• Luminescent image analyzer, LAS-3000 (Fujifilm, Düsseldorf) 
• Magnet stirring bar retriever, MR3001 (Heidolph, Schwabach) 
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• Microscope, SM-LUX (Leitz, Wetzlar) 
• Multipipetter, Multipette plus (Eppendorf, Hamburg) 
• pH measuring device, HI 9321 (Hanna Instruments, Kehl am Rhein) 
• Phosphor Imager (Bio-Rad, München) 
• Photometer, BioPhotometer (Eppendorf, Hamburg) 
• Pipetter, pipetus-akku (Hirschmann, Eberstadt) 
• Pipettes, 0.5-10 µl, 10-100 µl an 100-1000 µl, Research (Eppendorf, Hamburg) 
• Refrigerator (Bosch, München) 
• Scintillation counter, Packard Tri-Carb 2100TR (Packard Bioscience, Groningen, 
Netherlands) 
• Shaker, HS 250 basic (IKA Labortechnik, Staufen) 
• Sonicator, Vibra Cell (Sonics & Materials, Danbury, Connecticut, USA) 
• Sorvall centrifuge, RC5C plus (Kendro, Langenselbold) 
• Sterile working station, KR-130 and KR-210 (Kojair, Vilppula, Finland) 
• Table top centrifuge, 5417 (Eppendorf, Hamburg) 
• Table top centrifuge, Biofuge A (Heraeus, Osterode) 
• Thermomixer, comfort and compact (Eppendorf, Hamburg) 
• Vortexer, Reax (Heidolph, Schwabach) 
• Weighing scales, 1265 MP (Sartorius, Göttingen) 
• Western Blot chamber, Mini-Protean 3 Electrophoresis Module Assembly (Bio-Rad, 
München) 
• X-ray developer, Curix HT-530 AGFA (AGFA, Köln) 
 
3.1.2 Laboratory Supplies 
• Bürker counting chamber (Brand, Wertheim) 
• Cell culture flasks, T25 and T75 (Nunc, Roskilde, Denmark) 
• Cell culture 24-well plates (Becton Dickinson, Heidelberg) 
• Centrifuge tubes, Sorvall GS3 (Kendro, Langenselbold) 
• Centrifuge tubes, Sorvall SA-600 (Kendro, Langenselbold) 
• Columns, Econo Column (Biorad, München) 
• Concentrator, Minicon B15 (Millipore, Schwalbach) 
• Cuvettes (Sarstedt, Nümbrecht) 
• FACS tubes (Sarstedt, Nümbrecht) 
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• Film cassette, 20 x 25 cm (Bio-Rad, München) 
• Filter, 40 µm (Falcon, Heidelberg) 
• Gel blotting paper GB003 (Schleicher and Schuell, Dassel) 
• Glass pipettes (Brand, Wertheim) 
• Glass plates, outer glass PLT W/1.5 mm, M-P 3 (Bio-Rad, München) 
• Glass plates, short plates, M-P 3 (Bio-Rad, München) 
• Glass plates, outer plates 16 x 20 cm (Bio-Rad, München) 
• Glass plates, inner plates 16 x 20 cm (Bio-Rad, München) 
• Latex gloves (Kimberly-Clark, Zaventem, Belgium) 
• Microcentrifuge tubes, 1.5 ml (Sarstedt, Nümbrecht) 
• Microplates, flat-bottom 96 well plate (Nunc, Roskilde, Denmark) 
• Nitrocellulose membrane Trans-blot transfer medium, pure (Bio-Rad, München) 
• One-way pipettes, 5 ml, 10 ml and 25 ml (Grenier, Nürtingen) 
• Phosphor screen, Imaging Screen K (Bio-Rad, München) 
• Pipette Combitips, 2.5 ml, 5 ml and 10 ml (Eppendorf, Hamburg) 
• Pipette tips, 1-10 µl and 10-1000 µl (Sarstedt, Nümbrecht) 
• Pipette tips, 100-1000 µl (Eppendorf, Hamburg) 
• Plastic tubes with tops, 15 ml and 50 ml (Falcon, Heidelberg) 
• Plastic wrap (RUF, Bremen) 
• Polystyrene columns (Pierce, Rockford, IL USA) 
• Polystyrene tubes with tops, 13 ml (Sarstedt, Nümbrecht) 
• Sponges, 8 x 11 cm (BioRad Laboratories, München) 
• Syringes, 10 ml and 20 ml (Braun, Melsungen) 
• Vacuum filter, Stericup 0.22 µm GP ExpressPlus (Millipore, Schwalbach) 
• X-OMAT UV Plus Film (Kodak, Stuttgart) 
 
3.1.3 Cell Culture Media and Additives 
• Ampicillin (Roche, Mannheim) 
• β-Mercaptoethanol (Merck, Darmstadt) 
• Culture medium IMDM (Lonza, Verviers, Belgium) 
• Culture medium RPMI 1640 (Lonza, Verviers, Belgium) 
• Fetal calf serum (PAA, Cölbe) 
• G418 (PAA, Pasching, Austria) 
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• Isopropyl-β-thiogalactopyranoside (MBI Fermentas, St. Leon-Rot) 
• L-glutamine, 200 mM (Lonza, Verviers, Belgium) 
• Non-essential amino acids (Lonza, Verviers, Belgium) 
• Phophate Buffered Saline (PBS) without Ca2+ and Mg2+ (Lonza, Verviers, Belgium) 
• Penicillin/Streptomycin, 10,000 U/ml + 10,0000 µg/ml (Lonza, Verviers, Belgium) 
• Sodium chloride (KMF, Leipzig) 
• Sodium pyruvate (Lonza, Verviers, Belgium) 
• Tryptone (Merck, Darmstadt) 
• Yeast extract (Gibco BRL, Karlsruhe) 
 
3.1.4 Immunoglobulin Synthesis and ELISA Reagents 
• Biocoll, Ficoll 1.077 g/ml (Biochrom, Berlin) 
• Ethylenediaminetetraacetic acid (EDTA) (Merck, Darmstadt) 
• Goat anti-human IgG (Sigma, Steinheim) 
• Goat anti-human IgM (Sigma, Steinheim) 
• Goat anti-human IgG alkaline phosphatase conjugate (Sigma, Steinheim) 
• Goat anti-human IgM alkaline phosphatase conjugate (Sigma, Steinheim) 
• Heparin sodium, 5000 (Ratiopharm, Ulm)  
• Human IgG (Sigma, Steinheim) 
• Human IgM (Sigma, Steinheim) 
• p-Nitrophenyl phosphate tablets (pNPP) (Sigma, Steinheim) 
• Pokeweed mitogen (Biochrom, Berlin) 
• Sodium carbonate (Merck, Darmstadt) 
• Sodium hydrogen carbonate (Merck, Darmstadt) 
• Sodium hydroxide, 2 N (Behringwerke, Marburg) 
• Tris-(hydroxymethyl)-aminomethane (Tris Base) (Merck, Darmstadt) 
• Tris buffer tablets (Sigma, Steinheim) 
• Tween 20 (Merck, Darmstadt) 
 
3.1.5 SDS-PAGE Reagents and Western Blot Antibodies  
• Acetic acid, 100 % (Merck, Darmstadt) 
• Acylamide/bisacrylamide, 30 % (Serva, Heidelberg) 
• Ammonium persulfate (BioRad Laboratories, München) 
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• Bromphenol blue (Riedel-de-Haën, Hannover) 
• Buffer strips for anode and cathode, Excel Gel SDS (Amersham Pharmacia Biotech, 
Uppsala, Sweden) 
• Ethanol, absolute (J.T. Baker, Deventer, Netherlands) 
• Fat-free milk powder Sucofin (Trade Service International, Zeven) 
• Glycine (Sigma, Steinheim) 
• Goat anti-biotin conjugated HRP (Cell Signaling, Beverly, MA, USA) 
• Goat anti-rabbit conjugated HRP (Cell Signaling, Beverly, MA, USA) 
• Horse anti-mouse conjugated HRP (Cell Signaling, Beverly, MA, USA) 
• Kerosene (Fluka, Buchs, Switzerland) 
• LumiGLO reagent and peroxide (Cell Signaling, Beverly, MA, USA) 
• Methanol (RWTH University Hospital, Aachen) 
• Molecular weight marker, Dalton VII-L (Sigma, Steinheim) 
• Mouse anti-NFAT1 (BD Transduction Laboratories, Lexington, KY, USA) 
• Coomassie tablets, PhastGel Blue R-350 (Amersham Pharmacia Biotech, Uppsala, 
Sweden) 
• Ponceau S (Fluka, Buchs, Schweiz) 
• Polyacrylamide pre-cast gel, Excel SDS Homogenous 12.5 (Amersham Pharmacia 
Biotech, Uppsala, Sweden)  
• Protein marker, biotinylated (Cell Signaling, Beverly, USA) 
• Rabbit anti-c-Fos (Cell Signaling, Beverly, MA, USA) 
• Rabbit anti-ERK1/2 (Cell Signaling, Beverly, MA, USA) 
• Rabbit anti-phospho ERK1/2 (Cell Signaling, Beverly, MA, USA) 
• Rabbit anti-phospho MEK1/2 (Cell Signaling, Beverly, MA, USA) 
• Sodium dodecyl sulfate (Merck, Darmstadt) 
• Sodium orthovanadate (Sigma, Steinheim) 
• N, N, N’, N’ – Tetermethylethylenediamine (Sigma, Steinheim) 
 
3.1.6 Electrophoretic Mobility Shift Assay (EMSA) Reagents 
• [α-32P] ATP, 3000 Ci/mmol (Hartmann Analytik, Braunschweig) 
• AP-1 oligonucleotides (TIB Molbiol, Berlin) 
• dATP, dCTP, dGTP, dTTP, 100 mM (MBI Fermentas, St. Leon-Rot) 
•  [γ-32P] ATP, 3000 Ci/mmol (Hartmann Analytik, Braunschweig) 
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• Klenow Fragment, 300 U (MBI Fermentas, St. Leon-Rot) 
• Klenow buffer, 10 x (MBI Fermentas, St. Leon-Rot) 
• 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (Bio Whittaker, 
Heidelberg) 
• NF-κB oligonucleotides (Dr. M. Wöltje, RWTH University Hospital, Aachen) 
• Poly(dI-dC) (Amersham, Freiburg) 
• T4 polynucleotide kinase (Amersham, Freiburg) 
 
3.1.7 FACS Reagents and Antibodies 
• Anti-goat (Becton Dickinson, Heidelberg) 
• Goat anti-GST (Amersham Pharmacia Biotech, Uppsala, Sweden) 
• Goat anti-mouse conjugated FITC (Dianova, Hamburg) 
• Goat anti-mouse conjugated PE (Becton Dickinson, Heidelberg) 
• Goat anti-mouse (Dianova, Hamburg) 
• Lysing solution (Becton Dickinson, Heidelberg) 
• Mouse anti-human (Fab')2 IgM (Dianova, Hamburg) 
• Mouse anti-human HLA-DR (L243) (Prof. N. Koch, University Bonn; isolated from 
hybridoma supernatant) 
• Mouse anti-human HLA-DR (D1-12) (Prof. N. Koch, University Bonn; isolated from 
hybridoma supernatant) 
• Mouse anti-human HLA-DP (BraFB6) (Dr. Rebmann, University Hospital, Essen; 
isolated from hybridoma supernatant) 
• Mouse anti-human HLA-DQ (Tü22) (Prof. A. Ziegler, Charité University, Berlin; 
isolated from hybridoma supernatant) 
• Mouse anti-human CD19 conjugated FITC (Becton Dickinson Pharmingen, 
Heidelberg) 
• Mouse anti-human CD79a conjugated PE (Becton Dickinson, Heidelberg) 
• Mouse anti-human HLA-DR conjugated PE (Becton Dickinson, Heidelberg) 
• Mouse anti-human UH-1 (Prof. Fleischer, Bernhard Nocht Institute, Hamburg; 
isoalted from hybridoma supernatant) 
• Mouse IgG1, k conjugated PE isotype (Becton Dickinson, Heidelberg) 
• Mouse IgG2a, κ conjugated PE isotype (Becton Dickinson, Heidelberg) 
• Mouse immunoglobulins (Dianova, Hamburg) 
  Materials and Methods 
 19
• Fluo-4 (Molecular Probes, Eugene, OR, USA) 
• Propidium iodide (Sigma, Steinheim) 
 
3.1.8 Miscellaneous Reagents 
• Aqua ad iniectabilia (Braun, Melsungen) 
• Aqua irrigation solution (Delta Select, Pfulingen) 
• Bisindolylmaleimide II (Sigma, Steinheim) 
• Bovine serum albumin (Fluka, Buchs, Switzerland) 
• Bradford reagent (Biorad, München) 
• Calcimycin A23187 (Merck, Darmstadt) 
• Calcium chloride (Merck, Darmstadt) 
• Cyclosporin A (Alexis Corporation, Lausen, Switzlerand) 
• Deoxycholic acid (Fluka, Buchs, Switzerland) 
• Detoxi-Gel AffinityPak pre-packed columns (Pierce, IL U.S.A.) 
• Dithiothreitol (DTT) (Sigma, Steinheim) 
• Ethanol, 70 %, denatured (RWTH University Hospital, Aachen) 
• Genistein (Sigma, Steinheim) 
• Glucose (Merck, Darmstadt) 
• Glutathione reduced buffer (Merck, Darmstadt) 
• Glycerine (Merck, Darmstadt) 
• Hydrochloric acid, 32 % (Merck, Darmstadt) 
• 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (Merck, Darmstadt) 
• Magnesium chloride (Merck, Darmstadt) 
• Pefabloc SC (Roche, Mannheim) 
• Phytohemagglutinin (PHA) (Becton Dickinson, Heidelberg) 
• Potassium chloride (Merck, Darmstadt) 
• Protease inhibitor cocktail (Sigma, Steinheim) 
• Sepharose 4 Fast Flow (Amersham Pharmacia Biotech, Uppsala, Sweden) 
• Sodium azide (Merck, Darmstadt) 
• Sodium chloride (Merck, Darmstadt) 
• Sodium phosphate (Fluka, Buchs, Switzerland) 
• Thrombin protease (Amersham, Freiburg) 
• Triton X-100 (Merck, Darmstadt) 
  Materials and Methods 
 20
• U0126 (Cell Signaling Technology, Beverly, MA, USA) 
 
3.1.9 Commercially Available Kits 
• Human Annexin V/FITC-Kit (Bender MedSystems Diagnostic, Vienna, Austria) 
• ImmunoPure Fab Preparation Kit (Pierce, Rockford, IL USA) 
• ImmunoPure IgG Purification Kit (Pierce, Rockford, IL USA) 
• QiaQuick Nucleotide Removal Kit (Qiagen, Hilden) 
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3.2 Methods 
3.2.1 Cell Cultures 
The different cell lines listed in Table 3.1 were cultured in a CO2 incubator maintained at 
37°C, 5 % CO2, and high saturated air humidity. The cells were examined under a microscope 
twice a week and transferred into fresh medium (1 ml cells + 10 ml medium). Fetal calf serum 
(FCS) was inactivated at 56°C for 30 minutes. 
Table 3.1 – Cell Lines and Hybridomas 
Cell Line/Hybridoma Medium Supplements 
BJAB1 
BraFB62 
HuT786 
Raji3 
RJ2255 
 
RPMI 1640 
10 % FCS 
1 % L-glutamine 
1 % penicillin / 1 % streptomycin 
 
BJAB.GFP.NFAT4 
 
RPMI 1640 
10 % FCS 
1 % L-glutamine 
1 % penicillin / 1 % streptomycin 
500 µg/ml G418 
 
D1-125 
 
RPMI 1640 
10 % FCS 
1 % L-glutamine 
1 % penicillin / 1 % streptomycin 
100 µM β-mercaptoethanol 
 
L2435 
 
IMDM 
10 % FCS 
1 % L-glutamine 
1 % penicillin / 1 % streptomycin 
 
Mono Mac13 
 
RPMI 1640 
10 % FCS 
1 % L-glutamine 
1 % penicillin / 1 % streptomycin 
1 % nonessential amino acids 
1 % sodium pyruvate 
1 Prof. Ritter (RWTH University Hospital, Aachen) 
2 Dr. Rebmann (University Hospital Duisburg-Essen, Essen) 
3 Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ), Braunschweig 
4 Dr. Guerini (Novartis, Basel, Switzerland) 
5 Prof. Koch (University Bonn, Bonn) 
6 Prof. Fleischer (Bernhard Nocht Institute, Hamburg) 
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3.2.2 Fluorescence-activated Cell Sorting (FACS) 
Background: 
Flow cytometry is an immensely important field that allows one to assess cell surface 
markers, sort cells according to different characteristics, perform intracellular staining, 
determine the progress of the cell in the cell cycle, etc. The name can be misleading since not 
every FACS machine can sort cells. 
Cells flow through a nozzle into a stream of sheath fluid where it then enters a light path. The 
cells reach an interrogation point where a focused light beam hits the cells, and the cells are 
then analyzed for reflection, diffraction, or refraction of light or fluorescence. A photodiode 
measures forward-angle scatter (FSC) light and a photodetector detects side scatter light 
(SSC), and together they report the size and granularity of the cells. Other photodetectors 
equipped with colored filters detect fluorescence. After the light passes through the 
photodetectors, the light signals are transformed into electrical signals. Each photodetector 
provides a parameter that can be adjusted by changing the photodetector voltage and amplifier 
gain.  
Reagents: 
o PBS, 1 x 
o FCS 
o Lysing solution 
o Antibodies 
Procedure: 
1. The cells were adjusted to a concentration of 1 x 106/ml in PBS / 1 % FCS 
2. 1 ml was transferred into each FACS tube 
3. The tubes were centrifuged for 10 min. at 300 g and RT, and the supernatant was 
discarded 
4. For the detection of transmembrane proteins (e.g. CD79a), each pellet was 
resuspended in 2 ml diluted lysing solution (1:10), and this was incubated in the dark 
for 10 minutes 
5. Step 3 was repeated  
6. For indirect labelling, the pellet was resuspended with the primary antibody and left to 
incubate for 20 min. at RT (for direct labelling, step 7 was the next step) 
7. 1 ml PBS / 1 % FCS was added to each tube, and the tubes were centrifuged for 10 
min. at 300 g and RT 
8. The supernatant was discarded 
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9. The pellet was resuspended with fluorescent secondary antibody or directly labelled 
antibody and left to incubate for 20 min. at RT in the dark 
10. Step 5 was repeated 
11. The supernatant was discarded, and the pellet was resuspended in 500 µl PBS / 1 % 
FCS 
12. The samples were analyzed with a FACSCalibur or FACScan 
 
3.2.3 Antibody Purification 
Background: 
For purification of mouse IgG antibodies from hybridoma supernatants, the ImmunoPure kit 
(Pierce/ThermoFischer Scientific) was used. To capture IgG antibodies, Protein G isolated 
from the cell walls of group A Streptococcus is known to bind to mammalian antibody Fc-
binding sites. Today, Protein G is usually a recombinant form produced in Escherichia coli 
that no longer has albumin and cell-surface binding sites. The affinity of Protein G for 
mammalian IgG is higher than Protein A, another protein isolated from Staphylococcus 
aureus with similar properties, but Protein G cannot bind IgM, IgD, and IgA. Protein G is 
immobilized by attaching it to agarose beads before being packed into polystyrene columns. 
The bound antibodies can be washed and contaminants can be removed before being eluted 
with a low pH (2.8) buffer. 
Reagents: 
o Immobilized Protein G slurry 
o IgG binding buffer 
o IgG elution buffer 
o Polystyrene column with cap 
o 0.02 % sodium azide  
o 1 M Tris-HCl (pH 7.5) 
Procedure: 
1. Filtered hybridoma supernatant was concentrated (up to 25-fold) so that the total 
amount was no more than 12 ml 
2. The same amount of binding buffer was added to the concentrated antibody sample  
3. The column was packed with 2 ml immobilized Protein G slurry 
4. The column was equilibrated with 5 ml binding buffer 
5. The diluted antibody sample was added and allowed to flow through the column 
6. The antibodies were washed with 10 ml binding buffer 
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7. The antibodies were eluted with 6 ml elution buffer into microcentrifuge tubes 
containing 100 µl Tris-HCl, pH 7.5 
8. Another 5 ml elution buffer was added to remove any additional antibodies 
9. 10 ml 0.02 % sodium azide was added, and the column was stored at 4°C until further 
use 
10. The concentration of the antibodies was determined via Bradford protein assay (see 
3.2.6) and binding capability was analyzed with FACS (see 3.2.1) 
 
3.2.4 Fab Preparation and Purification 
Background: 
Pepsin and papain are two important enyzmes that can break down antibodies into smaller 
fragments. Papain is a cysteine protease used to generate Fabs or antigen binding fragments. 
Papain cleaves antibodies above the hinge region containing the disulfide bonds that join the 
heavy chains into two monovalent Fab fragments and one intact Fc (crystallizable) fragment.  
By further purifying the antibodies with immobilized Protein A, thereby removing the Fc 
portion, Fab fragments can be used for experiments where the Fc region can be problematic, 
e.g. binding to Fc receptors.  
Pepsin is a digestive protease commonly found in vertebrates. Pepsin cleaves the heavy chains 
of antibodies near the hinge region so that two Fab regions remain joined together, F(ab')2 
(remains divalent with two antibody binding sites), whereas the Fc fragment is digested into 
small peptides. Anti-IgM F(ab')2 antibodies were purchased and used for various experiments 
found in this work (calcium flux, stimulation of B cells for Western blot analysis, and 
EMSA).  
Reagents: 
o Immobilized papain slurry 
o Sample buffer: 20 mM sodium phosphate, 10 mM EDTA, pH 7.0 
o Digestion buffer: 20 mM cysteine-HCl dissolved in sample buffer 
o L243 antibodies 
o 10 mM Tris-HCl, pH 7.5 
o Immobilized Protein A column 
o Protein A IgG binding buffer 
o IgG elution buffer 
o 0.02 % sodium azide  
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Procedure: 
1. 42 mg cysteine-HCL was mixed with 12 ml phosphate buffer 
2. 500 µl papain slurry was taken up in 4 ml digestion buffer 
3. The mixture was centrifuged for 10 min. at 500 g and RT 
4. The supernatant was discarded, and step 3 was repeated 
5. After discarding the supernatant, the immobilized papain was resuspended in 500 µl 
digestion buffer 
6. L243 was mixed with the 500 µl papain/digestion buffer 
7. The papain and L243 combination was mixed overnight at 37°C 
8. 1.5 ml 10 mM Tris-HCl, pH 7.5 was added to the papain/L243 mixture 
9. The mixture was centrifuged for 10 min. at 500 g 
10. The supernatant containing the L243 Fab fragments was purified with a Protein A 
column  
11. For purification, the procedure described in 3.2.3 was used except the Fab fragments 
were collected during the wash step with Protein A IgG binding buffer and were not 
eluted into microcentrifuge tubes containing Tris-HCl  
12. The concentration of the Fab fragments was determined via Bradford protein assay 
(see 3.2.6) 
 
3.2.5 Superantigen Purification 
Background: 
Recombinant expression of wild-type staphylococcal enterotoxin A (SEA) was achieved by 
using Escherichia coli BL21 containing a pGEX vector with SEA-encoding DNA (kindly 
provided by Prof. J.D. Fraser, Auckland, New Zealand). Superantigen production is a four-
step process, which involves: 
1) Growth of the bacterial culture and induction of superantigen production with IPTG 
2) Harvesting the superantigens by lysing the cells and filtering out the cell debris 
3) Separating the superantigens from the other proteins by way of affinity 
chromatography 
4) Removal of contaminating endotoxins  
SPEA and MAS were produced in a similar manner, but were generated by lab personnel. 
After the superantigens were obtained, the concentration was measured (see 3.2.6), and SDS-
PAGE was performed to confirm purity (see 3.2.8). 
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Part One – Bacterial Growth and Superantigen Induction 
Reagents: 
o LB medium (10 g tryptone, 5 g yeast extract, 5 g NaCl, 1000 ml Aqua dest., pH 7.5) 
o Ampicillin (80 mg/ml) 
o IPTG, 1 M 
Procedure: 
1. Two cultures containing 75 ml LB medium, 75 µl ampicillin, and 1 µl glycerine 
culture were incubated overnight at 37°C and 250 rpm 
2. 4 x 25 ml of overnight culture were transferred into four 2 L flasks containing 500 ml 
LB medium plus 500 µl ampicillin 
3. The four 2 L flasks were left to incubate at 37°C and 250 rpm until they reached an 
O.D.600nm of 1.0 
4. Upon reaching an O.D. of 1.0, four 500 µl samples were taken from each flask for 
later analysis with an SDS gel 
5. 50 µl IPTG was added to each flask, and the flasks were then incubated at 30°C and 
250 rpm for three hours 
6. After three hours, four 500 µl samples were taken from each flask (SDS gel), and the 
bacterial cultures were transferred to six 500 ml centrifuge tubes 
7. The tubes were centrifuged for 20 min. at 4000 g and 4°C 
8. The supernatant was removed (but not discarded!) whereupon another 500 µl sample 
of the supernatant was taken (SDS gel). 25 ml of the removed supernatant was 
transferred back into each of the tubes and the pellets were resuspended 
9. 6 x 25 ml vortexed mixture was placed into six 50 ml plastic tubes 
10. The tubes were centrifuged for 30 min. at 4000 g and 4°C 
11. A 500 µl aliquot (SDS gel) was taken from the supernatant, and the rest was discarded 
12. The pellets were frozen at -80°C before continuing with part two 
Part Two – Harvesting the Superantigens 
Reagents: 
o Lysis buffer (2.9 g NaCl, 6.06 g Tris base, 0.37 g EDTA, 1 % Triton X-100, pH 8) 
o PBS, 1 x 
Procedure: 
1. The pellets were thawed on ice 
2. The pellets were resuspended in 15 ml lysis buffer and with the aid of a pipette, all of 
the clumps were removed  
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3. The mixture was poured into a 300 ml Erlenmeyer flask on ice 
4. The mixture was sonicated 10 times for 10 sec. with one minute intervals at intensity 
level 5 
5. 100 µl of the sonicated mixture was drawn for the SDS gel 
6. The mixture was transferred back into six plastic 50 ml tubes and centrifuged for 30 
min. at 43,000 g and 4°C 
7. A 500 µl aliquot was taken (SDS gel), and the supernatant was filtered with a 0.22 µm 
sterile filter 
8. Another 500 µl aliquot was drawn from the filtered fluid 
Part Three – Affinity Chromatography 
Background: 
Affinity chromatography is very useful for separating and purifying biomolecules with a high 
specificity and selectivity. Affinity chromatography requires the presence of a ligand that can 
bind the protein of interest. In this case, the glutathione-S-transferase (GST-Tag from 
Schistosoma japonicum) tag found encoded in the pGEX vector and now present in the 
protein, binds to the glutathione ligand in the sepharose matrix. The desired protein can be 
obtained by introducing a competitor into the appropriate elution reagent (reduced glutathione 
buffer), which reduces the affinity of the desired protein attached to the matrix. The protein 
may also contain a protease cleavage site (here it is thrombin), and after cleavage, the protein 
can be eluted using PBS. 
Reagents: 
o PBS, 1 x 
o Reduced glutathione buffer (0.155 g reduced glutathione, 2.5 ml 1 M Tris-HCl, pH 8, 
and 47.5 ml Aqua irrigation solution) 
o Ethanol, 70 % 
o Thrombin, 1 Unit / µl 
Procedure: 
1. The column was rinsed twice with distilled water 
2. The column was then rinsed once with PBS with a small portion of PBS remaining at 
the bottom of the column 
3. 6 ml vortexed sepharose beads was added to the column 
4. The sepharose beads were allowed to settle overnight in the refrigerator 
5. The column was then rinsed with 100 ml PBS leaving enough PBS to cover the 
sepharose beads 
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6. The filtered supernatant containing the superantigens was added to the column and 
allowed to run through. A 500 µl aliquot was taken for the SDS gel 
7. The column was rinsed again with 100 ml PBS, and another aliquot of the flow-
through was taken for the SDS gel 
8. The superantigens’ GST-Tags were cleaved with thrombin using 3 ml of the thrombin 
solution with a concentration of 1 Unit / µl 
9. The column was incubated overnight with thrombin 
10. Five fractions were collected on ice using PBS. The first four fractions contained 4 ml, 
and the last fraction had 6 ml. A 100 µl aliquot was taken from each fraction for an 
SDS gel 
11. The fractions were frozen at -20°C 
12. The column was regenerated with 50 ml reduced glutathione buffer, and another 
aliquot for the SDS gel was taken 
13. The column was rinsed with 50 ml PBS followed by 10 ml Aqua irrigation solution, 
and then the column was stored with a combination of 5 ml 70 % ethanol and 5 ml 
Aqua irrigation solution at 4°C 
Part Four – Endotoxin Removal 
Background: 
After producing recombinant superantigens, it is important to remove any contaminating 
pyrogens that would interfere with cell stimulation experiments. Lipopolysaccharides (LPS) 
activate different cells including monocytes and macrophages, which lead to a broad spectrum 
of cellular responses such as changes in the differentiation process and production of 
cytokines. Polymyxin B belongs to a family of antibiotics containing a cationic cyclopeptide 
and a fatty acid chain. Immobilized polymixin B effectively removes endotoxins by binding 
to the lipid A portion of LPS. 
Reagents: 
o Endotoxin removing gel in columns 
o 1 % sodium deoxycholate 
o PBS, 1 x 
o Ethanol, abs. 
Procedure: 
1. The gel in the column was regenerated by washing it with five column volumes of 1 % 
sodium deoxycholate, followed by 3 column volumes of PBS 
2. The gel was equilibrated with 3 column volumes of PBS 
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3. The sample was applied to the column and left to incubate for one hour 
4. PBS was used to collect the samples 
5. Step 1 was repeated 
6. The column was stored in 25 % ethanol at 4°C 
 
3.2.6 Calculating the Protein Concentration 
Background: 
The Bradford protein assay was used to determine the protein concentration. This assay is 
based on the acidic dye known as Coomassie Brilliant Blue G that complexes with proteins. 
The absorption maximum of this dye changes in the presence of proteins and acidic milieu 
from 465 nm to 595 nm. The Coomassie dye binds to basic and aromatic amino acid residues, 
particularly arginine. A standard using either IgG or BSA needs to be established before the 
actual samples can be measured. The micro assay was performed, which detects proteins with 
a concentration in the range of 1-25 µg/ml. 
Reagents: 
o Bradford reagent 
o IgG (1 mg/ml) dissolved in water 
o Bovine serum albumin (BSA) (1 mg/ml) dissolved in water or in buffer C used for the 
nuclear extract samples 
o Aqua irrigation solution 
Procedure: 
1. The standards were made according to Table 3.2 
Table 3.2 – Standards for the Micro Protein Assay 
Standard BSA or IgG Aqua Concentration (after adding 200 µl 
Bradford Reagent) 
1 1 µl 799 µl 1 µg/ml 
2 2.5 µl 797.5 µl 2.5 µg/ml 
3 5 µl 795 µl 5 µg/ml 
4 10 µl 790 µl 10 µg/ml 
5 15 µl 785 µl 15 µg/ml 
6 25 µl 775 µl 25 µg/ml 
 
2. 200 µl Bradford reagent was added to the blank, each standard, and the sample 
3. The standards, blank, and samples were incubated for at least 5 minutes, but no longer 
than 30 minutes 
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4. The absorption was measured at 595 nm with a photometer 
 
3.2.7 Generating Cell Lysates 
Background: 
The sample buffer contains sodium orthovanadate to inhibit protein tyrosine phosphatases and 
alkaline phosphatases from removing phosphate groups that are important for the 
identification of phosphorylated proteins in Western blots.  
Reagents: 
o Antibodies (IgG, D1-12, BraFB6, Tü22) 
o Superantigens (SEA, MAS, TSST-1) 
o Sample buffer: 65 mM Tris-HCl, 25 % glycerine, 2 % SDS, 1 mM sodium 
orthovanadate, pH 6.8 
Procedure: 
1. Cells (BJAB, Raji, RJ225) were adjusted to a concentration of 1 x 106/ml  
2. Primary antibodies (1 µg/ml) or superantigens (250 ng/ml – 1000 ng/ml) were added 
3. When required, secondary antibodies (2 µg/ml) were added after ten minutes 
4. The samples were incubated for a total of 1 hour in a 24-well plate at 37°C, 5 % CO2 
5. Samples were centrifuged in microcentrifuge tubes for 1 minute at 20,000 g 
6. The supernatant was removed, and the pellets were resuspended in 100 µl sample 
buffer 
7. The samples were sonificated on ice (10 sec) 
8. The sonificated samples were boiled at 95°C for 3 min. 
9. The samples were stored at -20°C  
 
3.2.8 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Background: 
Sodium dodecyl sulfate is an anionic detergent that covers the charge of the proteins so that a 
constant negative charge is achieved. The disulfide bridges are broken after adding the buffer 
containing β-mercaptoethanol, and the secondary and tertiary structures of the proteins are 
disrupted after heating the samples at 95°C, reducing the proteins back to their primary, linear 
structure. The molecules are separated according to their molecular weight using 12.5% 
polyacrylamide gels. Pre-cast polyacrylamide gels were used for superantigens since the 
stability of the gels allows one to easily stain with Coomassie and preserve for further use. 
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Reagents: 
o Reduced SDS-loading dye/Laemmli buffer, 2 x: 10 ml 1.5 M Tris base (pH 6.8), 6 ml 
20 % SDS, 30 ml glycerol, 15 ml β-mercaptoethanol, 1.8 mg bromphenol blue 
o Molecular weight marker, Dalton VII 
o Kerosene 
Procedure: 
1. The heating block was preheated to 95°C 
2. The cooling apparatus was turned on and allowed to cool down to 15°C 
3. The samples were diluted 1:2 in Laemmli buffer 
4. The samples, molecular weight marker, and loading dye were incubated for 5 minutes 
at 95°C 
5. The ceramic plate was coated with 2 ml kerosene 
6. The polyacrylamide gel was placed on the ceramic plate with the white buffer strips 
applied to the cathode side of the gel next to the gel pockets and the yellow buffer 
strips applied to the anode side of the gel 
7. 10 µl of the marker and 13 µl of the loading dye and samples were pipetted into the 
gel pockets 
8. The electrophoresis ran for 75 min. at 600 V and 50 mA 
 
3.2.9 Coomassie Staining of Polyacrylamide Gels 
Background: 
The Coomassie dye is a convenient method for the visible detection of proteins with 
concentrations lying between 0.1-1 µg. The gel is fixed with a fixing solution that causes the 
proteins to precipitate and the SDS to diffuse out of the gel. This is followed by staining the 
gels with Coomassie dye, washing the excess dye with water, destaining the gel until only the 
stained protein bands are visible, and preserving the gel. 
Reagents: 
o Aqua dest. 
o Fixing solution: 400 ml ethanol abs., 100 ml acetic acid, 500 ml Aqua dest. 
o Coomassie dye: 1 tablet PhastGel Blue R dissolved in 400 ml destaining solution with 
the help of stirring and 60°C and then filtered afterwards 
o Destaining solution: 250 ml ethanol abs., 80 ml acetic acid, 670 ml Aqua dest. 
o Preserving solution: 50 ml glycerol, 450 ml destaining solution 
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Procedure: 
1. The gel was incubated in fixing solution for 30 minutes after which the fixing solution 
was discarded 
2. The gel was incubated for 30 min. to 1 hr in Coomassie dye until the marker bands 
were visible 
3. Distilled water was used to rinse the gel followed by a 1-2 hr incubation in destaining 
solution 
4. The gel was incubated in preserving solution for 30 minutes, wrapped in cellophane, 
and left to dry for two days 
 
3.2.10 Discontinuous SDS-PAGE 
Background: 
The same principal lies behind this SDS-PAGE with the exception of two-layered gels being 
made in preparation for Western blots. Two gels with different Tris/HCl buffers were used: a 
stacking and a resolving gel. The stacking gel concentrates the proteins before the proteins are 
separated in the resolving gel. 
Reagents: 
o Distilled water 
o Ammonium persulfate (APS) (10 %) 
o Bromphenol blue 
o β-mercaptoethanol 
o Stacking gel buffer: Tris-HCl (1.5 M, pH 8.8) 
o Resolving gel buffer: Tris-HCl (0.5 M, pH 6.8) 
o Electrophoresis buffer (5x): 0.12 M Tris base, 0.96 M glycine, 30 ml 10 % SDS, 600 
ml, pH 8.3 
o Acrylamide/Bisacrylamide (30%) 
o N,N,N’,N’-tetramethylethylenediamine (TEMED) 
o Biotinylated molecular marker 
Procedure: 
1. The glass gel plates were rinsed with 70 % ethanol, wiped clean with tissues, and then 
placed in the gel holders 
2. The reagents for the 10 % resolving gel were mixed according to Table 3.3, pipetted 
between the glass plates, layered with distilled water, and allowed to polymerize for 
20 minutes 
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Table 3.3 –Resolving Gel Reagents for SDS-PAGE 
Reagents for 1 10 % Resolving Gel Amount 
1.5 M Tris-HCl, pH 8.8 2.34 ml 
Aqua dest. 3.66 ml 
Acrylamide/bisacrylamide, 30% 3 ml 
APS, 10% 90 µl 
TEMED 20 µl 
 
3. The water was removed, the 4 % stacking gel was prepared as given in Table 3.4, the 
combs were placed in the gel, and the stacking gel was allowed to polymerize for 20 
minutes 
Table 3.4 –Stacking Gel Reagents for SDS-PAGE 
Reagents for 1 4 % Stacking Gel Amount 
0.5 M Tris-HCl, pH 6.8 910 µl 
Aqua dest. 2.08 ml 
Acrylamide/bisacrylamide, 30% 467 µl 
APS, 10% 35 µl 
TEMED 7.8 µl 
 
4. The gel comb was removed and the glass plates containing the polymerized gel were 
placed in the electrophoresis chamber 
5. The chamber was filled with 1 x electrophoresis buffer 
6. The samples and molecular weight marker received bromphenol blue and 1 % β-
mercaptoethnaol, were heated at 95°C for 3 minutes, and were then pipetted into the 
gel slots 
7. The electrophoresis ran at 150 V for 90 min. on ice  
 
3.2.11 Western Blot 
Background: 
A Western blot involves transferring the SDS-PAGE separated proteins from the 
polacrylamide matrix onto a nitrocellulose membrane with the help of an electrical field. A 
blot sandwich is created where the membrane is placed on the gel, and this is then surrounded 
by gel blotting paper and sponges. During Western blot transfer, the SDS is washed out so 
that the proteins are renatured and build their secondary and tertiary structures. In order to 
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prevent non-specific binding to the nitrocellulose membrane, the possible binding sites are 
blocked with fat-free milk powder. The detection of high affinity binding of the primary 
antibody to the protein of interest is achieved with a secondary antibody that is coupled with 
the horseradish peroxidase enzyme. This enzyme converts the substrate (luminol) into its 
oxidized form, which then emits light that can be detected on X-ray film.  
Reagents: 
o Transfer buffer: 25 mM Tris base, 0.2 M glycine, 20 % methanol, pH 8.5 
o Ponceau S-solution 
o TBS-buffer (10 x): 0.2 M Tris base, 2.28 M NaCl, pH 7.6 
o TBS/T buffer (1 x): TBS, 0.1 % Tween 20 
o Blocking buffer: 2.5 g fat-free milk powder dissolved in 50 ml TBS/T buffer 
o Primary antibody: 10 ml TBS-T, 5 % fat-free milk powder, and primary antibody 
(diluted 1:1000) 
o Secondary antibody: 10 ml TBS-T, 5 % fat-free milk powder, secondary antibody 
(diluted 1:2000), and HRP-conjugated anti-biotin antibody (diluted 1:1000) 
o Detection solution: 250 µl LumiGLO reagent (20 x), 250 µl LumiGLO peroxide (20 
x), and 4.5 ml distilled water for each gel 
Procedure: 
1. The nitrocellulose membrane and gel blotting paper are cut to fit the size of the gel 
2. The membrane, gel blotting paper, and sponges are equilibriated in transfer buffer 
3. The blot sandwich is formed and then placed in the blot module with the gel facing the 
cathode side and the membrane facing the anode side 
4. The cooling element is placed next to the blot module, and then the module is filled 
with transfer buffer 
5. The blot takes about 90 min. at 100 V 
6. The proteins can be visualized by placing the membrane in Ponceau S solution and 
then washed with distilled water to ensure proper blotting 
7. The Ponceau S solution can be completely removed with transfer buffer, and then the 
membrane can be rinsed with distilled water 
8. The membrane was incubated overnight with 25 ml blocking buffer at 4°C 
9. The membrane was then incubated with the primary antibody for 2 hrs at RT 
10. The membrane was washed 3 x with TBS/T buffer 
11. The membrane was incubated with the secondary antibody for 1 hr at RT 
12. Step 10 was repeated 
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13. The membrane was incubated in detection solution for 1 minute 
14. The membrane could then be detected either using X-ray film or a LAS-3000 imager 
 
3.2.12 FACS Apoptosis Assay 
Background: 
Apoptotic cells were determined using the human Annexin-V/FITC kit available from Bender 
Med Systems. Annexin-V can bind to phosphatidylserine, a molecule that is usually located 
on the inner side of the cell membrane, but during apoptosis, this molecule is transversely 
redistributed to the outer side of the membrane using a calcium-dependent flip-flop 
mechanism (Martínez and Freyssinet, 2001). Phosphatidylserine is now exposed and binds to 
Annexin-V, which is conjugated with the fluorescent marker, FITC. Propidium iodide is also 
added to distinguish between apoptotic (Annexin-V-positive and propidium iodide-negative) 
and necrotic (Annexin-V-positive and propidium iodide-positive) cells.  
Reagents: 
o PBS, 1 x 
o Binding buffer, 4 x 
o Propidium iodide (20 mg/ml) 
o AnnexinV-FITC 
o Aqua irrigation solution 
o Antibodies (IgG, D1-12, BraFB6, Tü22) 
Procedure: 
1. BJAB were adjusted to 1 x 106/ml and 1 ml was aliquoted in each well in a 24-
wellplate 
2. The cells received either no antibodies or 3 µg mouse IgG, D1-12, BraFB6, and Tü22, 
respectively 
3. The cells were incubated in a CO2 incubator for 3 hrs at 37°C and 5 % CO2  
4. After stimulation, cells were adjusted to 5 x 105/ml and transferred to FACS tubes 
5. The cells were centrifuged for 10 min. at 300 g and RT 
6. The supernatant was discarded, and the cells were washed with 1 ml PBS 
7. Step 5 was repeated 
8. The supernatant was discarded, and the cells were resuspended in 1 ml 1 x binding 
buffer, which had been diluted 1:4 with aqua irrigation solution 
9. 195 µl from each sample was transferred into new tubes where they received 5 µl 
AnnexinV-FITC 
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10. The samples were incubated in the dark for 10 min. 
11. The cells were washed with 1 ml PBS and then centrifuged for 10 min. at 300 g and 
RT 
12. 190 µl 1 x binding buffer was added to the pellet whereupon the cells then received 10 
µl propidium iodide 
13. The samples were analyzed with a FACS Calibur 
 
3.2.13 Calcium Flux Measurement with FACS 
Background: 
Changes in intracellular calcium concentrations can be assessed using fluorescent indicators 
that are sensitive to calcium and respond with a spectral shift, which can be measured with 
flow cytometry, fluorescence spectroscopy, or fluorescence microscopy. Fluo-4 is a calcium 
indicator that is nonfluorescent until it binds calcium and is excited with visible light. Fluo-4 
exhibits a quantum yield at saturating calcium of approximately 0.14 and has a Kd for Ca2+ of 
345 nM (Molecular Probes). To obtain maximum calcium flux, calcimycin was used. 
Although calcimycin A23187 displays antibacterial properties, calcimycin is known as a 
calcium ionophore that can increase intracellular concentrations of calcium. 
Reagents: 
o Antibodies (mouse IgG, D1-12, BraFB6, Tü22, anti-IgM F(ab’)2, and goat anti-mouse 
IgG) 
o Calcimycin A23187 
o Fluo-4  
o Measurement buffer: 5 mM glucose, 1 mM magnesium chloride, 1 mM sodium 
phosphate, 1.3 mM calcium chloride, 25 mM HEPES, 120 mM sodium chloride, 5.4 
mM potassium chloride, pH 7.35 
o Incubation buffer: same as measurement buffer + 0.3 % bovine serum albumin 
Procedure: 
1. Two types of buffers were prepared: incubation and measurement buffer 
2. Cells were adjusted to 1 x 106/ml in incubation buffer 
3. Fluo-4 was added for a final concentration of 1 µM 
4. The cells were incubated in a 37°C water bath for 30 minutes 
5. The cells were centrifuged for 10 minutes at 300 g and RT 
6. The cells were taken up in half the amount of measurement buffer so that the cell 
concentration was 2 x 106/ml 
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7. 500 µl was pipetted into FACS tubes 
8. FACS measurement was performed where the first 30 s were used as the baseline, 
followed by 2.5 minutes of measurement, and then 20 µM calcimycin was added for 
the last 30 s to achieve the maximum calcium flux 
9. A ten minute incubation period was allotted between primary and secondary antibody 
addition after which the measurement could be conducted  
 
3.2.14 Peripheral Blood Mononuclear Cell Isolation 
Background: 
Peripheral blood mononuclear cells (PBMC) differ from granulocytes and erythrocytes with 
their lower density making it easy to isolate PBMC using a Ficoll density gradient. Ficoll is 
composed of a high molecular polysaccharide and epichlorohydrin, a reactive organic 
compound. High density cells such as erythrocytes and granulocytes settle to the bottom of 
the gradient after centrifugation while low density cells like thrombocytes remain in the top 
phase. The PBMC form a layer directly above the Ficoll, and this interphase is removed and 
washed several times with PBS.   
Reagents: 
o Heparin (25,000 U/ml) 
o PBS, 1 x 
o Ficoll with density 1.077 g/ml 
o Whole blood 
Procedure: 
1. 50 ml whole blood containing 2500 U heparin was diluted 1:1 with PBS  
2. 25 ml of the blood/PBS mixture was slowly pipetted onto 25 ml Ficoll (altogether 4 
Falcon 50 ml tubes) 
3. The Ficoll gradient was centrifuged for 20 min. at 600 g and RT 
4. The interphase containing the PBMCs was slowly removed and placed in a new 50 ml 
Falcon tube where it was then filled to the top with PBS 
5. The PBMCs were centrifuged for 10 min. at 300 g and RT 
6. The pellets were washed twice with PBS 
7. The cell concentration was determined using a Bürker counting chamber 
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3.2.15 Immunoglobulin Synthesis 
Background: 
Antibody production is a crucial component of the adaptive immune response. By way of 
MHC-II presentation of antigen peptides on B cells and ensuing interaction with T cells, T 
cells can stimulate B cells to proliferate and differentiate into plasma cells. These antibodies 
have important functions for the elimination of pathogens such as neutralization, opsonisation 
for phagocytosis, activation of the classical complement cascade, and sensitization for killing 
by NK cells. A common mitogen used to stimulate immunoglobulin synthesis is pokeweed 
mitogen (PWM), a lectin derived from the plant Phytolacca americana. PWM activates B 
lymphocytes to undergo a proliferative response and differentiate into immunoglobulin 
secreting cells.        
Since part of the immunoglobulin synthesis experiments were carried out with anti-MHC-II 
antibodies, it was important to use non-specific mouse IgG antibodies to remove the factor of 
Fc receptor-mediated feedback inhibition of antibody production. Ligation of FcγRII provides 
an inhibitory signal through an immunoreceptor tyrosine-based inhibition motif, ITIM, which 
prevents immunoglobulin synthesis.  
Reagents: 
o RMPI medium containing 1 % penicillin/streptomycin, 1 % L-glutamine, 10 % FCS 
o Pokeweed mitogen (PWM) (40 ng/ml) 
o Antibodies (IgG, UH-1, BraFB6, Tü22) 
o Superantigens (SEA, TSST-1, MAS) 
Procedure: 
1. The isolated PBMCs were adjusted to a cell concentration of 5 x 106/ml 
2. 1.8 ml (=9 x 106 cells) was pipetted into 13 ml tubes with tops 
3. 4 ml medium was added, and the tube was centrifuged for 10 min. at 300 g and RT 
4. The supernatant was removed and step 4 was repeated 
5. The supernatant was decanted and the pellet was resuspended in 9 ml medium 
6. Each sample contained 3 ml cells (3 x 106)  + 1.5 ml PWM + 1 µg superantigens or 10 
µg antibodies 
7. 4 ml of each sample was pipetted into a 24-well plate (1 ml/well) 
8. Samples receiving anti-MHC-II antibodies were incubated for 30 minutes before 
secondary antibodies were added (20 µg goat anti-mouse antibodies) 
9. The 24-well plate was incubated for seven days at 37°C and 5 % CO2 
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3.2.16 Enzyme-linked Immunosorbent Assay (ELISA) 
Background: 
Sandwich ELISAs are useful for determining the presence of secreted products such as 
cytokines and immunoglobulins. This particular sandwich ELISA involves the immobilization 
of a capture antibody that is specific for IgG or IgM immunoglobulins onto the bottom of a 
96-well plate. The well-plate is then blocked with bovine serum albumin (BSA) to prevent 
unspecific binding of proteins. The titrated standards and samples containing 
immunoglobulins are added after removing excess antibodies from the 96-well plate. After 
incubation of the samples/standards, excess antibodies are again removed and then another 
antibody specific for the IgG or IgM antibodies conjugated with alkaline phophatase is added. 
After a further wash step, the substrate (p-Nitrophenyl phosphate) is added, which leads to a 
chemical reaction and change in color so that the absorption can now be measured with an 
ELISA reader.      
Reagents: 
o Carbonate buffer: 29 mM sodium carbonate, 22 mM sodium hydrogen carbonate, pH 
9.6 
o Coating buffer: Carbonate buffer + 1 % BSA 
o Dilution buffer: 1 L PBS + 400 µl Tween 20 + 3 % BSA 
o Dilution buffer + EDTA: Dilution buffer + 20 mM EDTA 
o Wash buffer: 2 L PBS + 1.25 ml Tween 20 
o Substrate: Each ELISA plate requires 1 Tris buffer tablet dissolved in 20 ml Aqua 
dest. + 1 pNPP tablet 
o Stop solution (2 N NaOH) 
o Coating antibodies, 1 mg/ml (goat anti-human IgG, goat anti-human IgM) 
o Standards (human IgG, human IgM antibodies) 
o Alkaline phosphatase conjugated goat anti-human IgG antibodies and IgM antibodies 
(1 mg/ml) 
Procedure: 
1. Goat anti-human IgG and goat anti-human IgM were diluted 1:1000 in carbonate 
buffer 
2. 100 µl/well was pipetted into a 96-well plate 
3. The well plates were coated in aluminium foil and incubated overnight at 4°C 
4. The well plates were washed 3 x with an ELISA washer 
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5. Each well received 200 µl coating buffer, and the well plates were incubated in the 
dark at RT for two hours 
6. Step 4 was repeated 
7. Standard solutions and samples were diluted with dilution buffer containing EDTA 
according to Table 3.5 
Table 3.5 – Standard Solutions and Sample Dilutions for ELISA 
Human IgG Standard Human IgM Standard Sample Dilutions 
50 ng/ml 200 ng/ml 1:5 
40 ng/ml 140 ng/ml 1:10 
35 ng/ml 120 ng/ml 1:25 
25 ng/ml 100 ng/ml 1:50 
20 ng/ml 80 ng/ml 1:100 
15 ng/ml 60 ng/ml 1:200 
5 ng/ml 20 ng/ml  
 
8. 100 µl standard or sample (in replicates) was diluted into each well 
9. The well plates were incubated for 2 hours in a 37°C water bath 
10. Step 4 was repeated 
11. The conjugated antibodies were diluted in dilution buffer without EDTA: goat anti-
human IgG (1:500) or goat anti-human IgM (1:2000) 
12. 50 µl of the conjugated antibodies was pipetted into each well 
13. Steps 9 and 10 were repeated 
14. 200 µl substrate solution was pipetted into each well and incubated for 35 minutes in 
the dark at RT 
15. The color reaction was stopped by pipetting 50 µl stop solution into each well 
16. The absorbance was measured in an ELISA reader at 492 nm 
 
3.2.17 Nuclear Extract Preparation 
Background: 
To determine the presence of transcription factors in an electrophoretic mobility shift assay, 
the nuclear proteins have to be isolated from the cells. Nuclear extract preparation is generally 
a two-step procedure where the cells are first incubated with a hypotonic buffer (in this case, 
Buffer A) that causes the release of the cytoplasmic components, and then the remaining 
nuclei are incubated in a high salt buffer (Buffer C), which causes the nuclei to swell and later 
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be mechanically disrupted so that after centrifugation, only the nuclear extract can be found in 
the supernatant. 
Reagents: 
o Anti-MHC-II antibodies (D1-12, BraFB6, Tü22) 
o Anti-IgM antibodies 
o Buffers A and C (listed below) 
o Cyclosporin A 
o Mouse IgG antibodies 
o PHA 
o PBS, 1 x 
o Sodium orthovanadate 
Procedure: 
1. The cell concentration was adjusted to 1 x 106/ml in a volume of 10 ml in 40 ml 
culture flasks and allowed to incubate for 24 hours 
2. 16 hrs prior to cell harvesting, one culture flask received 1 µg/ml cyclosporin A 
3. The other culture flasks received either 10 µg/ml PHA, 1 µg/ml mouse IgG, 1 µg/ml 
anti-MHC-II, or 1 µg/ml anti-IgM antibodies for one hour 
4. The nuclear extracts were obtained by using two types of buffers, A and C (Table 3.6) 
5. The components listed in bold were added shortly prior to nuclear preparation 
Table 3.6 – Buffer Compositions for Nuclear Extract Preparation 
Reagents for Buffer A Concentration 
HEPES, KOH, pH 7.6 10 mM 
KCl 15 mM 
MgCl2 1 mM 
DTT 1 mM 
Protease Inhibitor Cocktail 0.5 mM 
Pefabloc 0.5 mM 
Sodium orthovanadate 100 µM 
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Reagents for Buffer C Concentration 
HEPES, KOH, pH 7.6 20 mM 
NaCl 420 mM 
EDTA  0.2 mM 
Glycerine 25 % (v/v) 
DTT 0.5 mM 
Protease Inhibitor Cocktail 0.5 mM 
Pefabloc 0.5 mM 
Sodium vanadate 100 µM 
 
6. Cells were centrifuged in 15 ml Falcon tubes for 10 minutes at 300 g and RT 
7. The pellets were washed with a chilled buffer containing 1 x PBS and 100 µM sodium 
orthovanadate  
8. Cells were centrifuged for 5 minutes at 300 g and 4°C 
9. Steps 7 and 8 were repeated 
10. The pellets were resuspended in 1 ml chilled buffer A, transferred to microcentrifuge 
tubes, and placed on ice for 10 minutes 
11. The tubes were centrifuged for 5 minutes at 700 g and 4°C 
12. Supernatants containing cytoplasmic extracts were removed while the remaining 
pellets were resuspended in 80 µl chilled buffer C and incubated on ice for 20 minutes 
13. The tubes were centrifuged for 10 minutes at 15,000 g and 4°C 
14. Supernatants containing nuclear extracts were aliquoted, shock-freezed with liquid 
nitrogen, and stored at -80°C 
15. Protein concentration was determined according to Bradford protein assay (see 3.2.9) 
 
3.2.18 Electrophoretic Mobility Shift Assay (EMSA) 
Background: 
An EMSA or bandshift assay is commonly employed to examine protein-DNA interactions. 
This procedure gives insight on whether or not proteins can bind to a given DNA sequence 
and can also give information on the composition of the binding complex by adding 
antibodies directed towards specific proteins (‘supershift’). The protein-DNA complexes are 
separated with electrophoresis on a polyacrylamide gel. Protein-DNA complexes move 
slowly through the gel resulting in a ‘shift’ compared to the quickly moving, smaller 
radioactively labelled oligonucleotides that are found at the end of the polyacrylamide gel.  
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Two different methods were used to gain information on the presence of AP-1 and NF-κB in 
B cell-stimulated nuclear extracts. The oligonucleotide containing the AP-1 consensus 
sequence with the sense strand reading 5'-CGCTTGATGACTCAGCCGGAA-3' and the 
antisense strand 5'-TTCCGGCTGAGTCATCAAGCG-3' was end-labelled with [γ-32P] ATP 
using a T4 polynucleotide kinase. The oligonucleotide containing the NF-κB consensus 
sequence with the sense strand reading 5´-TGCCTGGGAAAGTCCCCTCA-3´ and the 
antisense strand reading 5´-AGTTGAGGGGACTTTCCCAGG-3´ had the recessed 3´ ends 
filled in with Klenow fragment, a large fragment of DNA polymerase I from Escherichia coli. 
The Klenow fragment possesses 5´→3´ polymerase activity and 3´→5´ exonuclease activity, 
but lacks the 5´→3´ exonclease activity of DNA polyemerase I. 
Reagents: 
o Aqua iniectabilia 
o AP-1-specific oligonucleotides 
o NF-κB-specific oligonucleotides 
o Bandshift buffer, 10 x: 100 mM Tris-HCl, pH 7.4, 50 mM MgCl2, 1 M KCl, 50 % 
(v/v) glycerine, and 100 mM DTT 
o dIDC 
o Klenow buffer 
o Klenow fragment 
o Nucleotides (-dATP) 
o T4 polynucleotide kinase 
o [α-32P] ATP 
o [γ-32P] ATP 
Procedure (for AP-1): 
1. T4 polynucleotide kinase was dissolved in 25 µl aqua iniectabilia for 3 minutes 
2. 5 µl sense AP-1 oligonucleotides was added to one tube containing dissolved T4 
polynucleotide kinase, and 5 µl anti-sense AP-1 oligonucleotides was added to another 
tube containing to the same 
3. 18 µl aqua iniectablia was added to each tube 
4. 2 µl [γ-32P] ATP (110 TBq/mmol) was added to each tube, and these tubes were 
incubated for 30 minutes at 37°C 
5. The sense and anti-sense AP-1 oligonucleotides were combined 
6. Denaturation took place afterwards by heating the tubes to 95°C for 5 minutes 
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7. The thermomixer was turned off, and the oligonucleotides were allowed to anneal 
overnight at RT 
8. 20 µg nuclear extract (adjusted to 12 µl with aqua iniectabilia) was combined with 
bandshift buffer (2 µl/reaction), 1 µg/ml dIDC (1 µl/reaction), and 5 µl radioactively 
labelled oligonucleotides and incubated for 30 minutes 
Procedure (for NF-κB): 
1. Components listed in Table 3.7 were pipetted into a microcentrifuge tube and then 
incubated at 30°C for 30 minutes 
Table 3.7 – Reagents for NF-κB EMSA 
Reagents  Amount  
(-dATP) Nucleotide mix (10 mM/dNTP) 2.5 µl  
10 x Klenow buffer 2 µl  
Oligonucleotide 1 pmol/µl 1 µl  
Aqua iniectabilia 8.5 µl 
Klenow fragment (300 U) 1 µl 
[α-32P]-ATP (110 TBq/mmol) 5 µl 
 
2. Nucleotides (radioactive and non-radioactive) were removed using a QiaQuick 
Nucleotide Removal Kit 
3. 200 µl PN buffer was added to the 20 µl radioactively-labelled oligonucleotides 
4. This mixture was pipetted onto the provided column filter and then centrifuged for 1 
min. at 2000 g and RT 
5. The bound oligonucleotides were washed twice with PE buffer containing ethanol and 
centrifuged again for 1 min. at 2000 g and RT 
6. Residual buffer was removed by centrifugation at 10,000 g for 1 min. 
7. The oligonucleotides were incubated with 100 µl Aqua dest. for 1 min. before being 
centrifuged into a new microcentrifuge tube for 1 min. at 12,0000 g 
8. 1 µl including pipette tip was placed into a 6 ml scintillator cup before being measured 
with a Packard Tricarb 2100TR scintillator   
9. The results were calculated according to Cherenkov and given in the units counts per 
minute 
10. Step 8 was repeated from the procedure on AP-1 with the exception of the 5 µl 
radioactively labelled oligonucleotides being replaced with radioactively labelled NF-
κB emitting 20,000-40,000 cpm   
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3.2.19 Native Polyacrylamide Gels for EMSA 
Background: 
Unlike SDS-PAGE, the protein-oligonucleotide complexes, which migrate more slowly than 
the free oligonucleotides, are separated under non-denaturing conditions with a native 
polyacrylamide gel.   
Reagents: 
o Acylamide gel 
o Loading dye, 10 x 
Procedure: 
1. The glass gel plates were rinsed with 70 % ethanol, wiped clean with tissues, and then 
placed in the gel chambers which were further strengthened with gel holders 
2. The reagents for the acrylamide gel (see Table 3.8) were mixed, pipetted between the 
glass plates, a comb was inserted, and the gel was allowed to polymerize for 1 hour  
Table 3.8 –Native Polyacrylamide Gel Reagents for EMSA 
Reagents for 1 Gel Amount 
10 x TBE buffer 900 µl 
Glycerine 2.7 ml 
Acrylamide/bisacrylamide, 30% 6 ml 
Aqua dest. 53 ml 
TEMED 58 µl 
APS, 10% 288 µl 
 
3. The gel chamber was released from the gel holder and placed in the gel electrophoresis 
apparatus 
4. The apparatus was filled with 0.25 x TBE buffer after which the comb was removed 
5. Pre-electrophoresis of the gels took place for 20-30 min. at 200 V 
6. 20 µl of the bandshift samples along with 2 µl 10 x loading dye were pipetted into 
each gel slot 
7. After gel loading, electrophoresis ran for approximately 2 hours at 200 V 
8. The gel was transferred to double-layered gel blotting paper, wrapped in plastic wrap, 
and vacuum-dried for 1 hour at 70°C 
9. The dried gel was placed in a gel cassette and was exposed to a phosphor screen 
overnight 
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10. The phosphor screen was examined with a phosphor imager using Quantity 
One/Personal FX software 
 
3.2.20 Statistical Significance and Program Analysis 
The results are based on a series of experiments (number of experiments is shown as n = x). 
The statistical significance was calculated using the Student t-test in the program SigmaPlot 
7.0 (SPSS, Chicago IL USA), and a p-value with less than 0.05 is denoted with *. For the 
calcium flux experiments, the program Flow Jo was used to obtain the kinetics diagrams 
(Tree Star Inc., San Diego, CA USA).  The other FACS diagrams were generated with 
CellQuest software (Becton Dickinson, Heidelberg) or WinMDI (Windows Multiple 
Document Interface for Flow Cytometry) (Scripps Research Institute, La Jolla, CA, USA). 
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IV. RESULTS 
Major histocompatibility complex class II (MHC-II) molecules are more widely known for 
their structural role in presenting processed peptides to the T cell receptor, but MHC-II 
molecules are also important for initiating signaling pathways. All three MHC-II isotypes, 
HLA-DR, HLA-DP, and HLA-DQ, were explored for their involvement in triggering calcium 
mobilization, dephosphorylation and activation of the transcription factor NFAT, activation of 
the ERK MAP kinase pathway as well as binding activity of another transcription factor, AP-
1. Superantigens were also applied to compare their ability of activating MAP kinases with 
monoclonal antibodies. One of the most discussed signaling pathways related to MHC-II 
molecules, apoptosis, was further examined in connection to MAP kinases. A third 
transcription factor, NF-κB, was analyzed for its possible participation in MHC-II signaling in 
B lymphocytes. In addition, the role of MHC-II molecules during an important humoral 
functional response, immunoglobulin synthesis, was investigated.  
 
4.1 MHC-II Ligation Induces Calcium Mobilization 
The levels of intracellular calcium are crucial for modulating cellular responses such as 
growth and differentiation, and therefore calcium levels must be highly regulated through 
interactions with calcium binding proteins and ion exchange mechanisms. Upon arrival of 
external signals such as the ligation of receptors with antigen or antibody (e.g. BCR, TCR, 
FcγRII), the intracellular calcium concentration rises due to influx of extracellular calcium 
through calcium channels and the release of calcium from intracellular stores such as from the 
endoplasmic reticulum. 
Calcium mobilization has been observed after oligomerization of MHC-II molecules obtained 
with primary and secondary antibodies, which differs from BCR and TCR only requiring 
primary antibodies to trigger a calcium flux. An MHC-II-dependent calcium response has 
been observed with B cell lines and primary B cells (Lane et al., 1990; Mooney et al., 1990). 
A recent study showed that the calcium response occurs in a non-isotype-specific manner in 
murine B lymphocytes (Nashar and Drake, 2006). For this work, the expression and overall 
binding ability of three MHC-II isotype-specific antibodies (D1-12 binds to HLA-DR, 
BraFB6 binds to HLA-DP, and Tü22 binds to HLA-DQ) was measured on the BJAB B cell 
line using flow cytometry before the calcium response was examined. All three isotypes are 
equally expressed on BJAB (Fig. 4.1).  
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Figure 4.1 – Expression of MHC-II on BJAB. BJAB expresses all three MHC-II isotypes with D1-
12 binding to HLA-DR (black), BraFB6 binding to HLA-DP (green), and Tü22 binding to HLA-DQ 
(blue). The filled red peak is the negative control that only received the secondary antibody, goat anti-
mouse conjugated FITC. Shown is a representative example of n=3. 
 
The calcium response was measured using the calcium indicator, Fluo-4 AM, in flow 
cytometry experiments. Since Fc receptors can also trigger a calcium response, mouse IgG 
antibodies served as the negative control, and these antibodies were also cross-linked with 
goat anti-mouse secondary antibodies. Crucial for the calcium flux measurement was the 
incubation period allotted between primary and secondary antibodies (10 minutes), which 
allows for adequate binding of the primary antibodies. The first 30 seconds was used for the 
establishment of a baseline, the next 2.5 minutes were acquired after adding the secondary 
antibody, and the last 30 seconds shows maximal calcium flux induced with 20 µM 
calcimycin, A23187, a calcium ionophore. Ionophores increase membrane permeability for 
ions by acting as artificial mobile ion carriers or channel formers. A23187 is a carboxylic 
antibiotic that can transport divalent ions like calcium into the cell in exchange for two 
hydrogen ions (Luckasen et al., 1974). 
Mouse IgG antibodies could not trigger calcium release, whereas all three anti-MHC-II 
antibodies induced a calcium flux (Fig. 4.2). These results demonstrate that the calcium 
response occurs independent of the MHC-II isotype in human B cells. The rate of calcium 
mobilization is the same for all three anti-MHC-II antibodies with the maximal MHC-II-
induced calcium release occurring within the first 20 seconds. The duration of the calcium 
response remains steady for the entirety of the measurement until calcimycin is added 
whereupon the levels of fluorescence and thus calcium release are equivalent for all cases.  
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Figure 4.2 – MHC-II-Induced Calcium Flux in BJAB. BJAB were incubated for ten minutes with 
either mouse IgG (A), D1-12 (B), BraFB6 (C), or Tü22 (D) anti-MHC-II antibodies before receiving 
secondary goat anti-mouse antibodies (dotted arrow). The cells were treated with 20 µM calcimycin 
after 2.5 minutes (solid arrow). Shown is a representative example of n=3. 
  
To understand more about the events leading up to calcium mobilization, inhibitors were used 
to determine the involvement of different kinases. Considering there are similarities between 
the B cell receptor and MHC-II signaling pathways, viable kinase candidates were sought 
using our knowledge of the B cell receptor. Ligation of BCR leads to the co-localization of 
tyrosine kinases and phosphorylation of ITAM tyrosines found on the non-covalently 
associated disulfide-linked heterodimers, Igα (CD79a) and Igβ (CD79b). These molecules 
then recruit the tyrosine kinase syk needed for the activation of Btk and phospholipase Cγ, 
whereby the latter kinase helps in generating inositol-1,4,5-triphosphate and calcium influx 
from the endoplasmic reticulum into the cytoplasm. Therefore, the tyrosine kinase inhibitor, 
genistein, was applied 15 minutes before calcium flux measurement took place using the anti-
HLA-DR antibody, D1-12, and anti-IgM F(ab')2 to examine the significance of tyrosine 
kinases in the MHC-II-induced calcium response (Fig. 4.3). 
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Figure 4.3 – Protein Tyrosine Kinases are Integral for MHC-II-induced Calcium Flux. BJAB 
were pre-treated with 50 µM genistein for 15 minutes before adding anti-IgM F(ab')2 (B) or D1-12 (C) 
(dotted arrow). The negative control (A) did not receive any antibodies. Only D1-12 required 
secondary antibodies before the calcium flux could be performed. The cells were treated with 20 µM 
calcimycin after 2.5 minutes (solid arrow). Shown is a representative example of n=3. 
 
Similar to BCR signaling, tyrosine kinases are an important upstream component of inducing 
a calcium flux in MHC-II signaling since no calcium flux could be observed after inhibiting 
tyrosine kinases with genistein (Fig. 4.3B, C). 
Extracellular signal-regulated kinases 1/2 (ERK 1/2) or classical MAP kinases were also 
examined with regards to their effect on calcium responses in MHC-II signaling. ERK1/2 is 
another component of BCR signaling, which can be activated through a variety of 
mechanisms including the tyrosine kinase syk that can recruit other adaptor molecules such as 
BNLK and SOS, and SOS can then activate Ras, an upstream molecule of the MAP kinase 
pathway. In order to evaluate the importance of downstream classical MAP kinases in MHC-
II mediated calcium response, the MEK1/2 inhibitor, U0126, which prevents ERK1/2 
phosphorylation, was applied 10 minutes before calcium flux was induced with D1-12 and 
anti-IgM F(ab')2 antibodies (Fig. 4.4).        
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Figure 4.4 – Classical MAP Kinases Are Not Involved in MHC-II-induced Calcium Flux. BJAB 
were pre-treated with 5 µM U0126 for 10 minutes before adding anti-IgM F(ab')2 (B) or D1-12 (C) 
(dotted arrow). The negative control (A) did not receive any antibodies. Only D1-12 required 
secondary antibodies before the calcium flux could be performed. The cells were treated with 20 µM 
calcimycin after 2.5 minutes (solid arrow). Shown is a representative example of n=3. 
 
The ERK1/2 kinases are not significant for inducing a calcium flux because the MEK1/2 
inhibitor, U0126, did not decrease nor inhibit a calcium response. Again, in this respect, 
MHC-II signaling parallels BCR signaling in that tyrosine kinases are required, but the 
downstream ERK1/2 kinases are not necessary for calcium mobilization.  
It may appear that MHC-II-mediated calcium flux can only occur with the presence of BCR, 
however the calcium response was also detected with the monocytic cell line, Mono Mac1, 
and the T cell line, HuT78, which do not express the BCR containing the heterodimers Igα 
(CD79a) and Igβ (CD79b) required for BCR-mediated calcium flux (Fig. 4.5). Only the 
BJAB B cell line expresses the transmembrane protein CD79a (Fig. 4.5A) while Mono Mac1 
and HuT78 do not express CD79a. In fact, the isotype control for Mono Mac1 and HuT78 
shows stronger fluorescence and binding compared to the anti-CD79a antibody.   
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Figure 4.5 – Expression of CD79a on BJAB, Mono Mac1, and HuT78. The filled red peak is the 
isotype control (IgG1, κ conjugated to PE) whereas the black peak represents CD79a expression on 
BJAB (A), Mono Mac1 (B), and HuT78 (C). Shown is a representative example of n=3. 
 
In addition to B cells, monocytes/macrophages are another group of antigen presenting cells 
that express MHC-II molecules, and activated human T cells can also express MHC-II. The 
functional role of antigen presentation on activated human T cells to other T cells remains 
unclear although speculations have been made that altered TCR/CD3-transduced signals may 
bias the phenotype to Th2 or T cell anergy may result upon a second encounter with an 
antigen presenting cell (Lombardi et al., 1996; Taams et al., 1999). The cell lines Mono Mac1 
and HuT78 both express HLA-DR (Fig. 4.6A, E). The same calcium flux experiments were 
carried out with Mono Mac1 and HuT78. Similar to BJAB, mouse IgG antibodies crosslinked 
with goat anti-mouse antibodies could not induce a calcium response in Mono Mac1 or 
HuT78 (Fig. 4.6B, F). Monocytes and T cells do not express BCR and thus anti-IgM 
antibodies could not induce a calcium response (Fig. 4.6C, G). Anti-HLA-DR, D1-12, was 
able to mobilize calcium in Mono Mac1 and HuT78 (Fig. 4.6D, H), showing that HLA-DR 
expressed on different cell types can contribute to the induction of calcium mobilization.  
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Figure 4.6 – MHC-II Expression and Calcium Flux with Mono Mac1 and HuT78. Mono Mac1 
(A) and HuT78 (B) show HLA-DR expression in black with red representing the corresponding 
isotype control. Mono Mac1 (B-D) and HuT78 (F-H) received mouse IgG (B, F), anti-IgM (C, G), and 
D1-12 (D, H) antibodies (dotted arrow). Mouse IgG and D1-12 required secondary antibodies before 
the calcium flux could be performed. The cells were treated with 20 µM calcimycin after 2.5 minutes 
(solid arrow). Shown is a representative example of n=3. 
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Even though MHC-II-induced calcium mobilization may rely on the B cell receptor to 
activate the tyrosine kinases that ultimately leads to the calcium response in B lymhocytes, 
this does not explain the mobilization of calcium on cell types that do not express the BCR. 
However, it is clear that ligation of MHC-II molecules triggers a calcium flux, and this event 
occurs independent of MHC-II isotype on the BJAB B cell line.  
 
4.2 NFAT Dephosphorylation and Activation is Enhanced by MHC-II 
Signaling 
Calcium mobilization is a prerequisite for the dephosphorylation of four classes of nuclear 
factor of activated T cells (NFAT), NFAT1-NFAT4. These are reliant on calmodulin, a 
calcium sensor protein, which can activate the phosphatase, calcineurin. Calcineurin 
dephosphorylates NFAT, leading to a conformational change and the exposure of a nuclear 
localization sequence that allows NFAT nuclear import. Thus far, NFAT has been shown to 
be expressed in different cells types (B lymphocytes, NK cells, mast cells, neurons, among 
others) and can be activated by different mechanisms such as signaling through B and T cell 
receptors as well as Fc receptors (Ho et al., 1994; Yaseen et al., 1993; Aramburu et al. 1995; 
Hutchinson and McCloskey, 1995; Shaw et al., 1988). However, NFAT has not been explored 
in the context of MHC-II signaling. 
BJAB cells were stimulated with mouse IgG, anti-MHC-II antibodies, phytohemagglutinin 
(PHA), and cyclosporin A (CsA), and cell extracts were generated and subjected to Western 
blot analysis (Fig. 4.7). PHA has been shown to activate NFAT in various B cell lines, and 
cyclosporin A, a well-described immunosuppressant, inhibits the calcineurin phosphatase 
(Yaseen et al., 1993). Both phosphorylated and dephosphorylated forms of NFAT were 
detected using anti-NFAT-1 (NFATc2, NFATp) antibodies. The phosphorylated form can be 
seen as the higher band due to the larger molecular weight. The negative and mouse IgG 
controls have both phosphorylated and dephosphorylated NFAT forms with slightly more 
phosphorylated NFAT, which shows a balance in activity of the cells. As expected, PHA 
stimulation leads to more dephosphorylated NFAT and cyclosporin A inhibits the 
dephosphorylation of NFAT resulting in only phosphorylated NFAT (Fig. 4.7B). 
Interestingly, the anti-MHC-II antibodies triggered the dephosphorylation of NFAT in BJAB 
cells (Fig 4.7A). According to densitometric analysis, the anti-MHC-II antibodies led to 30-35 
% more dephosphorlyated NFAT in comparison to the mouse IgG control (Fig. 4.7C).   
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Figure 4.7 – MHC-II Ligation Enhances the Dephosphorylation of NFAT-1 in BJAB. BJAB were 
stimulated for 10 minutes with primary antibodies including IgG, D1-12 (DR), BraFB6 (DP), and 
Tü22 (DQ) and then crosslinked with secondary goat anti-mouse antibodies for the remainder of one 
hour (A). BJAB were also stimulated for 16 hours with CsA (1 µg/ml) and 1 hour with PHA (10 
µg/ml) (B). The cell extracts (20 µg) were immunoblotted for NFAT-1, and the blot is representative 
of n=3. The bands were densitometrically analyzed and normalized to IgG, and the results are based 
on the three Western blot experiments +/- SEM with * indicating a significance of p<0.05 (C). 
 
The Western blot analysis shows that NFAT is dephosphorylated, but does not give any 
information pertaining to the actual activity of NFAT. For this task, the transfected 
BJAB.GFP.NFAT cell line carrying a GFP-NFAT reporter construct containing four direct 
repeats of the NFAT binding site (-286 to –257) of the IL-2 gene promoter was utilized to 
determine NFAT activity by way of GFP fluorescence.  
BJAB.GFP.NFAT cells received anti-MHC-II, anti-IgM, and mouse IgG antibodies for ten 
minutes followed by ligation with goat anti-mouse secondary antibodies for 50 minutes. GFP 
fluorescence increases significantly after one hour of ligation with anti-MHC-II antibodies, 
but the positive control (anti-IgM) did not show a significant rise in GFP fluorescence after 
only one hour (Fig. 4.8A). The rise in fluorescence must be attributed to another cause since 
GFP-NFAT transcription and translation generally take longer than one hour. 
BJAB.GFP.NFAT were incubated with either D1-12 (DR), anti-IgM, or a combination of the 
two for one hour, and the number of viable cells was assessed by gating around the population 
with the larger forward vs. side scatter (Fig. 4.8B). It was determined that the rise in 
fluorescence is most likely due to the autofluorescence of dead cells. The oligomerization of 
MHC-II molecules is known to trigger a caspase-independent form of cell death, and these 
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autofluorescing apoptotic cells are probably responsible for the increase in GFP fluorescence 
(see section 4.5).   
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Figure 4.8 – Activation of MHC-II Enhances Fluorescence of BJAB.GFP.NFAT due to a 
Decrease in Cell Viability. The mean fluorescence for BJAB.GFP.NFAT cells that received mouse 
IgG, anti-IgM, and anti-MHC-II antibodies over the period of one hour is depicted, and the samples 
were compared with IgG to determine significance (n=7) (A). The number of viable cells (gated 
populated with larger forward vs. side scatter) is shown after one hour with various antibodies (n=4) 
(B). * indicates a significance of p<0.05, and the standard error of means is shown. 
 
The incubation times were then extended and GFP fluorescence was measured over a period 
of 3, 6, and 24 hours where the secondary antibodies or succeeding stimulatory antibodies 
were first added after 30 minutes instead of 10 minutes (Fig. 4.9). Anti-IgM stimulation led to 
an increase in GFP fluorescence with time. Anti-HLA-DR antibodies alone do not increase 
NFAT activity compared to anti-IgM stimulation, but NFAT appears to be regulated 
according to the sequence of stimulatory events (Fig. 4.9A). Anti-IgM stimulation followed 
by anti-HLA-DR stimulation significantly increases NFAT activation after 3 and 6 hours 
compared to anti-IgM stimulation alone (Fig. 4.9B). Anti-HLA-DR stimulation followed by 
B 
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anti-IgM ligation or simultaneous activation of HLA-DR and IgM appears to have an 
inhibitory effect after 24 hours. NFAT activity seems to follow the series of physiological 
events that occur after antigen binding to surface immunoglobulin (IgM) followed by antigen 
presentation on MHC-II molecules leading to B and T cell interaction. This form of 
stimulation generates the largest NFAT response.   
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Figure 4.9 – IgM Stimulation Followed by HLA-DR Ligation Enhances NFAT Activity. The 
mean GFP fluorescence was also determined after 1, 3, 6, and 24 hrs of BJAB.GFP.NFAT cells 
receiving mouse IgG, anti-IgM and anti-HLA-DR antibodies (A), and the samples were compared 
with anti-IgM (B) (n=4). * indicates a p-value of <0.05, and the standard error of means is shown. 
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Importantly, there is no significant difference in the number of dead cells between the 
different types of stimulation. Anti-IgM stimulation followed by anti-HLA-DR ligation shows 
as many viable cells as vice versa (Fig. 4.10). Thus, the significant rise in GFP fluorescence in 
the sample containing IgM stimulation prior to HLA-DR stimulation after 3 and 6 hours 
cannot be attributed to an increase in autofluorescing apoptotic cells, but rather an increase in 
GFP fluorescence by enhanced NFAT activity.   
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Figure 4.10 – No Variation in Cell Viability Between anti-IgM Combined with anti-HLA-DR 
Samples. The number of viable cells (gated populated with larger forward vs. side scatter) is shown 
after six hours with various antibodies (n=4). The standard error of means is shown. 
 
Western blot analysis of BJAB.GFP.NFAT after six hours with the afore-described 
stimulation was performed (Fig. 4.11). The BJAB transfected cell line shows a different 
variation of phosphorylated and dephosphorylated NFAT. While the resting non-transfected 
BJAB cell line had equal levels of dephosphorylated and phosphorylated NFAT (Fig. 4.7), 
resting BJAB.GFP.NFAT has only phosphorylated NFAT. After IgM stimulation for six 
hours, NFAT becomes dephosphorylated. IgM followed by HLA-DR ligation shows more 
dephosphorylated NFAT than IgM and HLA-DR ligated simultaneously, which confirms the 
flow cytometry data (Fig. 4.9). However, the level of dephosphorylated NFAT is difficult to 
compare between samples receiving anti-IgM antibodies and samples receiving anti-IgM 
followed by anti-HLA-DR antibodies since the levels of both phosphorylated and 
dephosphorylated NFAT are higher in the anti-IgM sample. Prior incubation of 
BJAB.GFP.NFAT with genistein shows only phosphorylated NFAT, which is what one 
would expect after preventing calcium flux from activating NFAT, and bisindolylmaleimide 
II, an inhibitor of PKC, had a stimulatory effect leading to mostly dephosphorylated NFAT 
after IgM stimulation.   
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Figure 4.11 – Phosphorylated and Dephosphorylated NFAT-1 in BJAB.GFP.NFAT. 
BJAB.GFP.NFAT were stimulated with 10 µg/ml IgG, anti-IgM, or D1-12 (anti-HLA-DR) either 
alone or in combination with one another (IgM/DR is simultaneous and IgM+DR is IgM followed by 
HLA-DR stimulation) for six hours. BJAB.GFP.NFAT cells were also previously incubated for 10 
minutes with 50 µM genistein (Gen.) or 1 µM bisindolylmaleimide II (Bis II) before IgM stimulation. 
β-Actin shows equal loading of protein. Shown is a representative example of n=3. 
 
Taken together, after MHC-II stimulation of the B cell line BJAB, NFAT-1 is 
dephosphorylated after a calcium flux is initiated similar to IgM ligation. NFAT activity 
increases in BJAB.GFP.NFAT when IgM ligation is followed by HLA-DR ligation. 
Simultaneous activation of IgM and HLA-DR has an inhibitory effect after 24 hours. Thus, 
both IgM and MHC-II molecules are important in the regulation of NFAT activity. 
 
4.3 Involvement of Classical MAP Kinases in MHC-II Signaling 
MAP kinases can be activated by a variety of factors including mitogens, growth factors, and 
activation of integrins and different G-protein coupled receptors. MAP kinases can be 
triggered through the T and B cell receptor, which leads to differentiation and growth of the 
cell. MAP kinases have been characterized into six different groups (see 1.3). The classical 
MAP kinase cascade, which ultimately leads to the activation of the extracellular signal-
regulated kinase 1/2, is one of the main signal transduction pathways mediated by MHC-II. 
Over the past few years, the classical MAP kinases have also been shown to be activated after 
MHC-II ligation in an isotype-specific manner. Levéille et al. were able to demonstrate that 
ERK1/2 phosphorylation occurs only after HLA-DP ligation and not after HLA-DR ligation 
using the Ramos B cell line (Levéille et al., 2002). Using the Raji B cell line, MAP kinase 
phosphorylation was examined for all three MHC-II isotypes. To ensure that the 
phosphorylation of ERK1/2 is directly related to the activation of MHC-II molecules, RJ225, 
a B cell line displaying similarities with Raji and containing a defect in the class II 
transactivator (CIITA) responsible for gene expression of MHC-II, received the same 
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treatment with antibodies. The MHC-II expression was initially examined and found to be 
much lower on RJ225 compared to Raji (Fig. 4.12A, B). However, RJ225 should not express 
MHC-II due to the CIITA defect, and therefore with the aid of another anti-HLA-DR 
antibody directly coupled to phycoerythrin (PE) and the corresponding PE-labelled IgG2a 
isotype control, it was found that RJ225 does not express any HLA-DR compared to Raji 
(Fig. 4.12C, D). Indirect labeling of anti-MHC-II antibodies with fluorescein isothiocyanate 
(FITC) led to residual binding on RJ225, but MHC-II expression is absent on the RJ225 cell 
line. Raji expresses high levels of MHC-II similar to BJAB (see Fig. 4.1). After determining 
the lack of MHC-II expression on RJ225 and high expression of MHC-II on Raji, the 
phosphorylation of ERK1/2 was determined with Western blot anaylsis. 
           
          
Figure 4.12 – Expression of MHC-II on Raji and RJ225. Raji (A) shows high expression and 
RJ225 (B) shows low expression of all three isotypes with D1-12 binding to HLA-DR (black), BraFB6 
binding to HLA-DP (green), and Tü22 binding to HLA-DQ (blue). The filled red peak is the negative 
control that only received the secondary antibody, goat anti-mouse conjugated FITC. Directly labelled 
anti-HLA-DR antibodies (black) and corresponding isotype control (red) show HLA-DR expression 
for Raji (C) and no HLA-DR expression for RJ225 (D). Shown is a representative example of n=3. 
 
Raji B cells were incubated with anti-HLA-DR (D1-12), anti-HLA-DP (BraFB6) and anti-
HLA-DQ (Tü22) antibodies for ten minutes followed by secondary goat anti-mouse 
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antibodies for the remainder of one hour. Only the stimulation of HLA-DP and HLA-DQ 
molecules was consistently found to increase the phosphorylation of ERK1/2 (Fig. 4.13A). 
Total ERK1/2 protein levels do not deviate dramatically as indicated with the pan ERK1/2 
antibodies. The extent of ERK1/2 phosphorylation was significant compared to the IgG 
control with densitometric analysis showing more than twice the amount of phosphorylated 
ERK1/2 after stimulating HLA-DP and HLA-DQ and the positive PHA control showing more 
than three-fold the amount of activated ERK1/2 in Raji (Fig. 4.13C). No increase in ERK1/2 
phosphorylation could be detected in RJ225 after the addition of anti-MHC-II antibodies, 
demonstrating that MHC-II molecules are crucial for triggering the MAP kinase pathway 
(Fig. 4.13B). PHA stimulation of RJ225 still led to a two-fold increase in ERK1/2 
phosphorylation, which shows that non-specific mitogen stimulation can still activate the 
MHC-II negative cell line. 
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Figure 4.13 – Isotype-specific Differences in ERK1/2 Phosphorylation in Raji. Raji (A) and the 
MHC-II negative cell line RJ225 (B) were stimulated for one hour with primary and secondary 
antibodies including IgG, D1-12 (DR), BraFB6 (DP), and Tü22 (DQ). Raji and RJ225 were also 
subjected to PHA treatment (10 µg/ml). The cell extracts were immunoblotted for phospho and pan 
ERK1/2 (A, B). The bands were densitometrically analyzed and normalized to IgG (C, D). The 
immunoblots show an example of n=3 experiments, and the densitometric analysis is based on these 
three experiments +/- SEM with * representing a significance of p<0.05. 
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4.4 MAP Kinase Phosphorylation Levels Correlate with c-Fos Protein 
Levels and AP-1 Formation in MHC-II Signaling 
An upstream kinase from ERK1/2 was also analyzed, MEK1/2. MEK1/2 is normally 
responsible for the phosphorylation of ERK1/2 and therefore the levels of phosphorylated 
MEK1/2 should also be regulated in an isotype-specific manner. Similar to the ERK1/2 
Western blots, MEK1/2 phosphorylation levels also increase after stimulating Raji with anti-
HLA-DP and anti-HLA-DQ antibodies, but not with anti-HLA-DR antibodies (Fig. 4.14).  
Using the MEK inhibitor, U0126, MEK phosphorylation decreased. Although U0126 is not 
known to inhibit the phosphorylation of MEK1/2, but rather inhibits the kinase’s ability of 
phosphorylating ERK1/2, U0126 is a weak inhibitor of Raf, a MAP kinase located upstream 
of MEK1/2 (Wang and Studzinski, 2001). The partial inhibition in MEK phosphorylation 
corresponds with a decrease in c-Fos protein levels, indicating an important connection 
between MAP kinases and c-Fos in MHC-II signaling.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14 – MHC-II-induced MAP Kinase Phosphorylation Correlates with an Increase in c-
Fos Protein Expression. Raji cells were stimulated for one hour with primary and secondary 
antibodies including IgG, D1-12 (DR), BraFB6 (DP), and Tü22 (DQ). Raji cells were also treated with 
5 µM U0126 10 minutes prior to incubation with antibodies. The cell extracts were immunoblotted for 
phospho MEK1/2, c-Fos, and pan ERK1/2. The Western blots show a representative example of n=3.  
 
Since c-Fos protein levels are dependent on MAP kinase phosphorylation, this would also 
affect downstream events including the formation of the transcription factor, AP-1. AP-1 is 
either present as a homodimer consisting of Jun/Jun proteins or a heterodimer composed of 
Fos/Jun proteins. Earlier comparative analyses of the NFAT complex in human B and T 
lymphocytes have shown differences in the composition of AP-1 (Huo and Rothstein, 1995; 
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Yaseen et al., 1994). Native NFAT/AP-1 complexes from human T lymphocytes were 
generally composed of similar amounts of Jun and Fos while Burkitt’s lymphoma cells 
showed much higher amounts of Fos (Yaseen et al., 1994). According to the rise in c-Fos 
protein levels found here, it was of interest to determine if there would also be an increase in 
AP-1 formation. Nuclear extracts from HLA-DR, -DP, and –DQ stimulated Raji were allowed 
to bind to radioactively-labeled AP-1 oligonucleotides in an EMSA. Similar to the Western 
blot results, crosslinking only HLA-DP and HLA-DQ led to an increase in AP-1 formation 
(Fig. 4.15). As expected, nuclear extracts obtained from anti-IgM stimulated B cells could 
also bind to AP-1 oligonucleotides. Cyclosporin A did not enhance nor decrease AP-1 
binding. Jurkat stimulated with PHA served as the positive control. 
 
 
 
 
 
 
Figure 4.15 – MHC-II Isotype-specific Differences in AP-1 Formation. Nuclear extracts were 
obtained from Raji stimulated for 16 hours with CsA (1 µg/ml), 1 hour with IgG, D1-12, BraFB6, 
Tü22 and goat anti-mouse antibodies (1 µg/ml), 1 hour with anti-IgM F(ab')2 (1 µg/ml), and Jurkat 
stimulated for 1 hour with PHA (10 µg/ml) and applied to AP-1-specific oligonucleotides in EMSA. 
The EMSA results show a representative example of n=3 experiments.  
 
MHC-II signaling leads to the mobilization of calcium, which is imperative for NFAT1 
activation, but this pathway differs from MAP kinase activation since the U0126 inhibitor did 
not alter calcium flux nor is calcium mobilization an isotype-specific event. The classical 
MAP kinases regulate the expression and activation of AP-1, another transcription factor now 
found to be of importance for MHC-II-derived signaling.  
 
4.5 Superantigens Do Not Influence MAP Kinase Activation 
In addition to monoclonal antibodies, superantigens can also bind to MHC-II molecules. 
However, not all superantigens can cross-link MHC-II molecules, and oftentimes biotinylated 
superantigens or additional antibodies are used to aid superantigens in ligating MHC-II. The 
two superantigens used in this work were streptococcal pyrogenic exotoxin A (SPEA), which 
in its monomeric form binds to the α chain of MHC-II, and staphylococcal enterotoxin A 
(SEA), which can cross-link the α and β chain of MHC-II. This mode of MHC-II ligation 
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differs from monoclonal antibodies that can only ligate α chains or β chains but not a 
combination of both.  
Both superantigens were tested for their ability to bind to MHC-II expressed on Raji. After 
the process of cloning SEA in the pGEX4T-1 vector, the recombinant production of SEA 
yields a GST tag attached to the superantigen. Anti-GST antibodies can bind to GST, and this 
anti-GST antibody can be detected by a secondary antibody conjugated to FITC. According to 
the flow cytometry results, SEA can bind to MHC-II molecules on the Raji cell line (Fig. 
4.16A). To test SPEA binding, Raji cells were incubated with SPEA, and the SPEA specific 
antibody, UH-1, was allowed to bind to SPEA. UH-1 was detected with the PE-labeled 
secondary antibody. A visible shift in fluorescence shows that SPEA can bind to MHC-II 
expressed on Raji (Fig. 4.16B).    
     
Figure 4.16 – Superantigen Binding to Raji. The filled red peak is the negative control that received 
either goat anti-GST and anti-goat conjugated FITC antibodies (A) or mouse UH-1 and anti-mouse 
conjugated PE antibodies (B). The black peak represents SEA binding visualized with the help of goat 
anti-GST and anti-goat conjugated FITC antibodies (A) or SPEA binding visualized with mouse UH-1 
and anti-mouse conjugated PE antibodies (B). Shown is a representative example of n=3. 
 
After determining that the SPEA and SEA superantigens can bind to MHC-II expressed on 
Raji, the superantigens were then examined for their ability to activate MAP kinases. Thus 
far, MAP kinases have only been examined after activating T cells with superantigens (Torres 
et al., 2002). It is not known what effect superantigens have on the MAP kinase cascade in 
antigen presenting cells. The Tü22 antibody that binds to HLA-DQ was used as the positive 
control since it was previously found to activate MAP kinases (see Fig. 4.13A). Raji cells 
were incubated either with SEA alone, anti-GST antibody alone, or SEA was further cross-
linked with the anti-GST antibody (Fig. 4.17). Even though SEA can ligate MHC-II 
molecules and the anti-GST antibody can ligate SEA and theoretically encourage the 
migration of additional MHC-II molecules, the phosphorylation of ERK1/2 does not increase.  
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Figure 4.17 – SEA does not Induce MAP Kinase Phosphorylation. Raji cells were stimulated for 
one hour with primary and secondary antibodies including IgG and Tü22 (DQ). Raji cells were also 
incubated with the superantigen SEA (500 ng/ml) either with or without the presence of the antibody 
GST (1 µg/ml). The cell extracts were immunoblotted for phospho ERK1/2 and pan ERK1/2. The 
Western blots show a representative example of n=3. 
 
The same experiment was carried out with SPEA, and SPEA was further cross-linked with 
UH-1 (Fig. 4.18). PHA strongly activated the ERK kinases in Raji cells followed by anti-
HLA-DP and anti-HLA-DQ stimulation. Cyclosporin did not enhance ERK1/2 
phosphorylation. Similar to SEA, UH-1 alone, SPEA alone, and a combination of SPEA with 
UH-1 did not lead to an increase in ERK1/2 phosphorylation. Unlike the monoclonal 
antibodies that bind to HLA-DP and HLA-DQ, superantigen binding to MHC-II molecules 
does not appear to activate the classical ERK1/2 MAP kinase.  
 
 
 
 
 
 
       
 
Figure 4.18 – SPEA Does Not Induce MAP Kinase Phosphorylation. Raji cells were stimulated for 
one hour with primary and secondary antibodies including IgG, BraFB6 (DP), and Tü22 (DQ). Raji 
cells were also treated with PHA (10 µg/ml), CsA (10 µg/ml), or incubated with the superantigen 
SPEA (500 ng/ml) either with or without the presence of the antibody UH-1 (1 µg/ml). The cell 
extracts were immunoblotted for phospho ERK1/2 and pan ERK1/2. The Western blots show a 
representative example of n=3. 
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4.6 NF-κB Activation in MHC-II Signaling 
NF-κB activation has often been implicated in MHC-II signaling in monocytes and B cells 
(Trede et al., 1993, 1995; Altomonte et al., 1993; Leonardi et al., 1997). However, conflicting 
reports exist on the type of ligand that induces NF-κB binding and TNF-α release. Using the 
EBV negative B lymphoblastoid cell line JY, one group reports that the anti-HLA-DR 
antibody, L243, and anti-HLA-DR and –DP antibody, IVA12 increase TNF-α production, but 
the anti-HLA-DR antibody, 2.06 and superantigens TSST-1 and SEB do not affect TNF-α 
production (Altomonte et al., 1993). In monocytes, another group demonstrates that the 
staphylococcal superantigens (SEA and SEB) and TSST-1 induce IL-1β and TNF-α 
transcriptional activity (Trede et al., 1993). In a different study, MHC-II activation was shown 
to actually block a different NF-κB mediated event, the gene expression of IL-6 in resting B 
cells (Kim et al., 2001). In summary, the involvement of NF-κB in MHC-II-mediated 
signaling appears to differ in cell type and remains confusing at best. 
Before superantigens could be used to stimulate cells, contaminating lipopolysaccharide 
(LPS) was removed using a polymyxin B-containing column. After removing endotoxins, 
TNF-α release was no longer detected in ELISA, which demonstrates possible problems that 
could arise when superantigens are not purified. NF-κB binding was examined in the two B 
cell lines, BJAB and Raji. Cells were stimulated with an anti-HLA-DR antibody, L243, the 
staphylococcal superantigens, SEAwt or the mutant SEAH187A/H225A that can no longer bind to 
the β chain of MHC-II, or lipopolysaccharide (LPS). There was no dramatic increase in NF-
κB binding after stimulation with L243, SEA, or LPS in both of the cell lines (Fig 4.19A). 
LPS could not reproducibly increase NF-κB binding in these B cell lines, and therefore the 
monocytic cell line, Mono Mac1, was used since it reacts highly sensitive to LPS. Only LPS 
could shift the NF-κB:DNA complex to form a detectable band, whereas the anti-MHC-II 
antibodies and superantigens could not induce NF-κB binding (Fig. 4.19B).  The stimulation 
of BJAB and Mono Mac1 with MHC-II isotype-specific antibodies was conducted and 
compared, and again only LPS induced NF-κB binding in Mono Mac1 (Fig. 4.19C). 
Superantigens and anti-MHC-II antibodies appear to be incapable of inducing NF-κB binding 
in these B cell and monocytic cell lines, however this does not eliminate the possibility of 
MHC-II induced NF-κB activation in other APCs.  
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Figure 4.19 – No Increase in NF-κB Binding Activity after MHC-II Binding. BJAB (A, left) and 
Raji (A, right) were stimulated for one hour with the anti-HLA-DR antibody, L243 (5 µg/ml), 
superantigens (250 ng/ml), or LPS (250 ng/ml). Mono Mac1 (B) were also stimulated with 
superantigens, LPS, or primary (1 µg/ml) and secondary antibodies (2 µg/ml) including L243 (DR), 
BraFB6 (DP), and Tü22 (DQ). BJAB (C, left) and Mono Mac1 (C, right) were also compared for NF-
κB binding after incubation with anti-MHC-II antibodies and LPS. Shown is a representative example 
of n=3. 
 
4.7 MHC-II and Apoptosis 
MHC-II molecules also influence cellular events on a completely different level since these 
molecules are not only involved in growth and differentiation, but MHC-II molecules can also 
eliminate mature, differentiated cells using a caspase-independent pathway of cell death. An 
interesting aspect of MHC-II signaling is its unique method in inducing apoptosis. Generally, 
apoptosis requires extrinsic and intrinsic mechanisms such as contact with death receptors 
belonging to the tumor necrosis factor family as well as swelling / increase in permeability of 
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the mitochondrial membrane that ultimately lead to the activation of caspases or cysteine 
proteases, which are responsible for the degradation of the cell. However, MHC-II molecules 
do not require death receptors nor do they always trigger caspases. Instead, MHC-II ligation 
leads to the relocalization and translocation of protein kinase C (PKC), which is known to 
have direct nuclear targets (Nagy and Mooney, 2003). The inhibition of PKC blocks MHC-II-
mediated cell death while inhibition of tyrosine kinases has no effect (Bertho et al., 2002; 
Castaigne et al., 2002; Guo et al., 2003). 
Triggering MHC-mediated apoptosis appears to be dependent on the activation 
state/maturation stage of the cells. For example, MHC-II-mediated cell death can only occur 
with activated monocytes and mature dendritic cells (DCs) and not with primary monocytes 
or immature DCs, suggesting that MHC-II directed apoptosis is an alternative pathway that 
clears activated cells resistant to the Fas death pathway (Bertho et al, 2002; Castaigne et al., 
2002).  
The importance of the bivalency of antibodies for the induction of apoptosis in the BJAB cell 
line was examined using AnnexinV as a marker for apoptosis in a flow cytometry assay. Fab 
fragments of the anti-HLA-DR antibodies, L243, were generated and incubated either alone 
or with kappa-specific secondary antibodies. Crosslinking L243 Fab fragments with 
secondary antibodies induced apoptosis almost to the same level as whole L243 antibodies 
(Fig. 4.20). Monovalent binding to HLA-DR achieved with the Fab fragments cannot initiate 
apoptosis. 
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Fig. 4.20 – Ligated L243 Fab Fragments Induce MHC-II-mediated Apoptosis. The percent of 
AnnexinV positive and propidium iodide negative (PI-) cells was determined after 3 hours of 
incubation with the Fab, kappa-specific and L243 antibodies. L243 and Fab+kappa-specific antibodies 
were compared with all three controls (n=4). * indicates a significance of p<0.05, and the standard 
error of means is shown.   
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The association of MHC-II with other molecules is instrumental in the activation of signal 
pathways including apoptosis. An HLA-DR/CD18 complex was reported to be decisive on 
whether or not monocytes activate tyrosine kinases or cell death according to their ability to 
associate with lipid rafts (Zilber et al., 2005; Doisne et al., 2008). A recent discovery by Jin 
and colleagues has also revealed a novel tetraspanner, MPYS, to be directly involved in 
MHC-II-mediated apoptosis in murine B lymphocytes (Jin et al., 2008b). Here they also 
describe the contribution of ERK1/2 to apoptosis by demonstrating that after administering 
the MEK1/2 inhibitor PD-98059, apoptosis was greatly reduced (Jin et al., 2008b). Since the 
classical MAP kinases are usually responsible for growth and differentiation and not 
apoptosis (unlike p38), the effect of a different MEK1/2 inhibitor, U0126, was examined with 
BJAB. 
BJAB B lymphocytes were incubated with or without 5 µM U0126 and with anti-MHC-II 
antibodies for three hours, and again measured in an AnnexinV-specific flow cytometry 
apoptosis assay. U0126 does not halt apoptosis and therefore the classical MAP kinases do 
not appear to play a role in MHC-II mediated apoptosis using the human BJAB cell line (Fig. 
4.21A). Apoptosis appears to be increased after administering U0126, but U0126 is not 
cytotoxic for the cells as indicated by a cytotoxicity test measuring the viability of cells with 
propidium iodide (Fig. 4.21B). 
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Fig. 4.21 – MHC-II-mediated Apoptosis Does Not Rely on Classical MAP Kinases. The percent of 
AnnexinV+/Propidium iodide- cells was determined after 3 hours of incubation with D1-12 (anti-
HLA-DR), BraFB6 (anti-HLA-DP), and Tü22 (anti-HLA-DQ) antibodies (A). * shows a significance 
of p<0.05 when comparing samples receiving anti-MHC-II antibodies to their respective controls of 
IgG with or without U0126 (n=3). The percent of propidium iodide positive cells after 24 hours was 
determined with varying concentrations of U0126 (B). The standard deviation is shown for both. 
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4.8 The Effects of MHC-II Ligation on Immunoglobulin Synthesis 
Antibody production is one of the most important contributions of B cells in fighting 
pathogens and recurring infections. B cells can produce antibodies against certain microbial 
components without the presence of T cells, but generally they require helper T cells for 
proliferation and synthesis of immunoglobulins (see 1.8). Usually B cells take up foreign 
antigens with the B cell receptor, process the antigen into peptides, and present the peptides to 
T cells via MHC. The interaction between the T cell receptor and MHC molecule is a 
preliminary step for the T cells to gain proximity to B cells and signal the B cells to produce 
antibodies. By replacing the TCR with a monoclonal antibody or superantigen, more 
information regarding an MHC-II-derived influence on immunoglobulin production can be 
obtained. 
The subject of whether or not superantigens enhance or decrease a humoral immune response 
has been of much debate over the past 20 years. Low doses (0.01 ng/ml) of staphylococcal 
superantigens have been shown to promote vigorous immunoglobulin responses compared to 
high doses (100 ng/ml), which can profoundly inhibit immunoglobulin production (Stohl et 
al., 1998; Stohl and Elliott, 1995). The enhancement of the humoral B response to T 
dependent (TD) antigens and T independent antigens after in vivo stimulation of mice with 
superantigens has been shown and may involve T cell cytokine production modulated by the 
classical MAP kinases (Torres et al., 2002). However, in another study, superantigens were 
unable to boost the immune response to an ongoing influenza infection (Huang, et al., 2000). 
Thus the ability of superantigens to enhance a humoral immune response relies on a variety of 
factors including the dose of superantigens and type of infection. 
The effects of MHC-II mediated signaling on immunoglobulin synthesis was analyzed using 
the superantigens staphylococcal enterotoxin A (SEA) and Mycoplasma arthritidis-derived 
superantigen (MAS). Peripheral blood mononuclear cells (PBMC) were stimulated with 
pokeweed mitogen (PWM) and incubated with the superantigens for seven days. The 
concentration of IgG and IgM antibodies was measured using ELISA. Since immunoglobulin 
production varies greatly between individuals, the percent of immunoglobulins was compared 
between samples containing PWM alone and samples containing PWM with superantigens. 
Stimulating PBMC with either of the superantigens, SEA or MAS, led to a dramatic reduction 
in IgG and IgM production (Fig. 4.22).  
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Fig. 4.22 – Combined PWM and Superantigen Stimulation Reduces Immunoglobulin Synthesis. 
PBMC were isolated and incubated with PWM alone or in combination with 222 ng/ml SEA or MAS 
for seven days. The immunoglobulin production with superantigens was compared to the PWM 
control set to 100 % (n=4). Shown is the standard deviation with * representing a significance of 
p<0.05.   
 
The next task was to determine what was responsible for the decline in immunoglobulin 
synthesis, so the percent of viable B cells was determined using FACS. The immunoglubulins 
were analyzed from the supernatant and the remaining cells were incubated with anti-CD19 
antibodies and propidium iodide. SEA and MAS superantigens significantly reduced the 
number of viable B cells from around 4 % to less than 2 % (Fig. 4.23). Superantigens are not 
known to induce apoptosis in B cells most likely due to their difference in cross-linking 
MHC-II molecules (e.g. SEA can ligate α and β chains of MHC-II whereas monoclonal 
antibodies ligate α or β chains), and therefore the reduction in B cells must be attributed to a 
different mechanism (Gross et al., 2006). However, superantigens can crosslink T cells (via 
TCR) and B cells (via MHC-II), which brings T and B cells into close proximity. It has been 
discussed that direct contact with T cells is necessary since irradiated or mitomycin pre-
treated T cells abrogates superantigen-induced inhibition of immunoglobulin synthesis 
(Moseley and Huston, 1991). T and B cell interaction could trigger the Fas/FasL apoptotic 
pathway, which would lead to B cell death and could account for the decrease in viable B 
cells, and/or cytotoxic T cells can eliminate the B cells immediately using a CD95-
independent perforin-based pathway (Stohl et al., 1998).    
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Fig. 4.23 – Combined PWM and Superantigen Stimulation Reduces Viable B Cells. PBMC were 
isolated and incubated with PWM alone or in combination with SEA or MAS (222 ng/ml) for seven 
days. The number of viable CD19+ B cells (propidium iodide negative) after PWM and superantigen 
stimulation was compared to the negative and PWM-stimulated controls (n=4). Shown is the standard 
error of means with * representing a significance of p<0.05.   
 
PBMC were also incubated in the presence of PWM and the anti-MHC-II antibodies, BraFB6 
and Tü22. UH-1 was used as a non-specific IgG antibody to account for any reduction in 
immunoglobulin synthesis that is due to antibody negative feedback inhibition. IgM and IgG 
production were reduced to approximately 80 % with UH-1 antibody incubation, but this does 
not compare to BraFB6 and Tü22 antibody addition, which reduced IgM and IgG synthesis to 
around 40 % compared to the PWM control (Fig. 4.24).   
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Fig. 4.24 – Immunoglobulin Synthesis is Decreased after Combined PWM and anti-MHC-II 
Stimulation. PBMC were isolated and incubated with PWM alone or in combination with BraFB6 
(DP), Tü22 (DQ), or UH-1 (2.22 µg/ml) for seven days. The immunoglobulin production with 
antibodies was compared to the PWM control set to 100 % (n=4). Shown is the standard error of 
means with * representing a significance of p<0.05.   
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Again, the number of viable B cells was assessed to determine a cause for the reduction in 
IgM and IgG synthesis. Unlike the superantigens, the anti-MHC-II antibodies do not 
negatively affect the number of viable B cells, and thus the decrease in antibody production 
cannot be attributed to apoptosis (Fig. 4.25). Nor does antibody-dependent cell-mediated 
cytotoxicity (ADCC) mediated by natural killer cells appear to account for the drop in 
immunoglobulin synthesis. The Fc receptors of natural killer cells are able to recognize 
antibodies bound to pathogen-infected cells, and the natural killer cells can release perforin, 
granzymes, and cytokines that trigger apoptosis. However, there are still many viable B cells 
after seven days of incubation with the anti-MHC-II antibodies. In fact, a slight but not 
significant increase in viable B cells can be observed after using anti-MHC-II antibodies or 
IgG antibodies. A more likely cause for the decrease in immunoglobulin synthesis is that the 
anti-MHC-II antibodies inhibit the action of pokeweed mitogen stimulating the differentiation 
of naive B cells into plasma producing cells.  
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Fig. 4.25 – Combined PWM and anti-MHC-II Stimulation Do Not Decrease Viable B Cells. 
PBMC were isolated and incubated with PWM alone or in combination with BraFB6 (DP), Tü22 
(DQ), UH-1, and mouse IgG (2.22 µg/ml) for seven days. The number of viable CD19+ B cells 
(propidium iodide negative) after PWM and superantigen stimulation was compared to the negative 
and PWM-stimulated controls (n=3). Shown is the standard deviation.   
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V. DISCUSSION 
The role of MHC-II molecules as antigen presenting structures is clear, but the ability of 
MHC-II molecules to transduce signals into the cell and the types of signals and functional 
responses that are involved in these signal transduction pathways have yet to be clearly 
defined. The results of this work give new insight into the complex of signaling molecules 
initiated by MHC-II molecules expressed on B lymphocytes. The effects these signaling 
molecules have on cellular responses such as apoptosis and immunoglobulin synthesis were 
investigated. 
Although the activation of tyrosine kinases and mobilization of calcium by MHC-II molecules 
have been known for almost twenty years, certain elements of MHC-II-induced calcium flux 
and the subsequent downstream events have not been fully elucidated (Lane et al., 1990; 
Mooney et al., 1990). A study using mice has shown that ligation of murine MHC-II 
molecules, I-Ak, I-Ad, or I-Ek, induced mobilization of calcium, demonstrating that MHC-II-
induced calcium flux proceeds in a haplotype- and isotype-independent manner (Nashar and 
Drake, 2006). Using the human BJAB B cell line, this study shows for the first time that 
calcium flux occurs in an isotype-independent manner in human B lymphocytes. Ligation of 
HLA-DR, HLA-DP, or HLA-DQ leads to a calcium flux showing a similar response with all 
requiring approximately 20 seconds until full calcium mobilization has taken place and the 
duration of the response extends over two minutes. The participation of tyrosine kinases was 
confirmed as the general tyrosine kinase inhibitor, genistein, blocked calcium mobilization 
after IgM or MHC-II ligation. The MEK kinase inhibitor, U0126, could not abrogate the 
calcium response after IgM or MHC-II ligation.  
The similarities between IgM- and MHC-II-induced calcium flux are remarkable and have 
received notable attention over the past few years. Aggregation of MHC-II on antigen-primed 
B cells has been shown to lead to phosphorylation of Igα/β (CD79a/CD79b), the signal 
transducer of the B cell receptor, and MHC-II was coimmunoprecipitated with Igα/β (Lang et 
al., 2001). Furthermore, knock-down of Igβ with shRNA abrogated the MHC-II-induced 
calcium response (Jin et al., 2008a). Jin and colleagues could also show that the 
interconnecting peptide of the MHC-II α chain is required for its association with Igα/β since 
a mutant could no longer associate with the CD79a/CD79b heterodimer nor induce calcium 
flux.  
While the Igα/β heterodimer remains the most likely candidate for aiding MHC-II molecules 
in mobilizing calcium by activating the tyrosine kinases required for calcium flux, Igα/β is 
not expressed on all antigen presenting cells that can also induce calcium flux by MHC-II 
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ligation. The CD79a expression was measured on the monocytic cell line, Mono Mac1, and 
the HLA-DR expressing T cell line, HuT78. Even though both do not express CD79a, both 
types of cells were capable of mobilizing calcium after ligation of HLA-DR, but not after 
using anti-IgM antibodies. Calcium mobilization has also been reported in purified monocytes 
after cross-linking HLA-DR, reinforcing the fact that MHC-II-induced calcium mobilization 
can occur independent of Igα/β (Zilber et al., 2005). It was postulated that HLA-DR 
associates with CD38 in lipid rafts, and CD38 aids MHC-II in transducing calcium signals. 
Activated human T cells also express HLA-DR, and a publication has shown that using either 
a mixture of superantigens (SEA, SEB; SEC-1, SEC-2, and SEE) or anti-HLA-DR antibodies 
could induce activation and increase intracellular levels of calcium (Kanner et al., 1992). Here 
it was speculated that CD3 or CD28 could play a role in PLC-γ1 activation after HLA-DR 
ligation. 
The mobilization of calcium is an indisputable consequence of MHC-II ligation, but the 
purpose of calcium signaling is not apparent. Protein kinases that are involved in calcium 
mobilization such as Src and Syk may be important for cytokine production, IgM synthesis, or 
dendritic cell maturation (Al-Daccak et al., 1994; Tabata et al., 2000; Andreae et al., 2003). 
However, a factor that has been neglected and that is directly related to calcium mobilization 
is the activation of calcium-sensor proteins and the calcineurin phosphatase, which ultimately 
activates the transcription factor, NFAT. Using the same BJAB cell line that showed calcium 
mobilization, ligation of MHC-II led to the deposphorylation of NFAT in an isotype-
independent manner.  
The function of NFAT has been well-described in T cells since it binds to the promoter of the 
cytokine gene, IL-2 (Shaw et al., 1988). By using the calcineurin inhibitors, cyclosporin A or 
tacrolimus, NFAT remains inactivated and IL-2 driven proliferation is inhibited. These 
inhibitors are commonly employed in transplant recipients to suppress the immune system 
and prevent allograft rejection. B cells are also known to express NFAT, but since IL-2 is not 
produced by B cells, NFAT most likely plays a different role in B lymphocytes (Yaseen et al., 
1993). One important function of NFAT is the expression of CD5 on B-1 cells (Teutsch et al., 
1995; Berland and Wortis, 1998). B-1 cells differ from the conventional B-2 cells since they 
generally secrete IgM and do not ordinarily undergo somatic hypermutation. They usually 
develop in atypical areas such as in the fetus and in the liver and are only produced for a short 
time around birth (Janeway et al., 1999). However, BJAB is not a B-1 cell line, so NFAT 
must serve a different purpose.  
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In recent years, research pertaining to NFAT in processes like T and B cell activation, 
differentiation, and anergy has gained momentum (Winslow et al., 2006; Barrington et al., 
2006). Mice with B cells lacking NFATc1 and NFATc2 were shown to have elevated IgG1 
and IgE antibody levels and expanded populations of plasma cells, signifying the importance 
of NFAT in the normal homeostasis and differentiation of B cells (Peng et al., 2001). In this 
work, ligation of MHC-II molecules with anti-MHC-II antibodies reduced the synthesis of 
immunoglobulins. Perhaps an over-activation of NFAT created by stimulation through MHC-
II is a signal for the cell to decrease antibody production. When NFAT is absent, the synthesis 
of immunoglobulins may not occur in a controlled manner, leading to elevated levels of 
antibodies.  
Another interesting aspect is the increase in NFAT activity when the BCR is activated 
followed by MHC-II ligation. The order and timing of BCR- and MHC-II-derived signals 
have already been deemed important in calcium signaling in mice (Nashar and Drake, 2006). 
A ten minute stimulation of BCR prior to MHC-II ligation decreased the elevation in calcium 
levels, but this effect was abolished after stimulating the BCR for 150 minutes before cross-
linking MHC-II molecules. Nashar and Drake could also show that BCR ligation followed by 
simultaneous MHC-II and CD40 ligation induced a significant mobilization of calcium, but 
simultaneous ligation of the BCR and CD40 followed by MHC-II decreased the level of 
intracellular calcium (Nashar and Drake, 2006). In this work, 30 minutes was allotted between 
BCR and MHC-II stimulation of the BJAB.GFP.NFAT cell line, and this series of events had 
a stimulatory effect on NFAT activity. By adding the anti-MHC-II antibodies prior or 
simultaneous to BCR stimulation, NFAT activity decreased. BCR stimulus followed by 
MHC-II ligation and CD40/CD40L contact mimics physiological events where antigen 
binding to surface immunoglobulin is followed by antigen presentation on MHC-II molecules 
leading to B and T cell interaction. Activation of the B lymphocyte through the BCR followed 
by contact of MHC-II with the TCR would lead to an expected increase in activation of the B 
cell, which might explain the positive impact this order of events has on NFAT activation. 
An important cellular response in MHC-II signaling is apoptosis. MHC-II-mediated apoptosis 
became problematic after trying to determine the fluorescence of BJAB.GFP.NFAT cells, 
which showed autofluorescence instead of GFP fluorescence after adding anti-MHC-II 
antibodies. Fortunately there was no significant difference in the number of dead cells 
between the different types of stimulation that involved anti-IgM followed by anti-HLA-DR 
ligation and vice versa. The increase in NFAT activity seen after IgM stimulation followed by 
HLA-DR stimulation is not due to autofluorescing apoptotic cells, but an increase in GFP 
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fluorescence. Simultaneous activation of BCR and MHC-II also showed less NFAT 
dephosphorylation using Western blot analysis than IgM alone and BCR followed by MHC-II 
stimulation. 
Monoclonal antibodies specific for MHC-II and designed to initiate apoptosis are an 
interesting therapeutic tool for combating lymphoid malignancies (Nagy et al., 2002). 
Therefore, deciphering the pathways that contribute to MHC-II-mediated apoptosis should be 
of upmost importance. One important prerequisite for understanding MHC-II-directed 
apoptosis is knowing that the antigen binding fragment (Fab) alone is not sufficient for 
inducing apoptosis. The complete antibody, F(ab')2 portion of the antibody, or Fab fragment 
cross-linked with a secondary antibody is necessary for triggering apoptosis (Vidovic and 
Toral, 1998; Gross et al., 2006).  
Another important factor for understanding MHC-II-mediated apoptosis is determining the 
involvement of various kinases. Ligating MHC-II may eliminate mature cells such as 
monocytes/macrophages and dendritic cells, but during the process it may initiate a signaling 
cascade that could have other effects (Castaigne et al., 2002; Bertho et al., 2002). While 
various reports have implicated the involvement of PKC and lack of participation from 
protein tyrosine kinases, other kinases are currently being assessed for their role in MHC-II-
mediated apoptosis (Bertho et al., 2002; Castaigne et al., 2002; Guo et al., 2003). The MAP 
kinases are one major group of kinases currently been analyzed for their contribution to 
MHC-II-induced apoptosis. Using the murine K46 cell line, MHC-II ligation activated AKT, 
ERK, and p38 but not JNK kinases (Jin et al., 2008b). Only the inhibitor specific for ERK, 
PD98059, inhibited cell death while the other AKT- and p38-specific inhibitors, LY294002 
and SB203580, did not abrogate MHC-II-mediated cell death. This is unusual since the 
extracellular signal-regulated kinases are usually responsible for cellular proliferation and 
differentiation. Generally, ERK protects cells from apoptosis and a lack or disruption of ERK 
may encourage apoptosis (Zhang et al., 2003; Purcell et al., 2007). Using a different inhibitor 
that inhibits MEK from phosphorylating ERK, U0126, the same experiment was carried out 
in the BJAB cell line, which is also susceptible to apoptosis. Inhibition of ERK did not disrupt 
apoptosis in this system, and therefore the actual participation of ERK1/2 in the MHC-II-
induced apoptotic pathway remains questionable.  
However, the activation of the classical MAP kinases has been described in monocytes and B 
cells without reference to apoptosis, and this signaling pathway was further analyzed in the 
Raji B cell line (Matsuoka et al., 2001; Leveille et al., 2002). The Raji B cell line was better 
suited for this line of experiments since a MHC-II negative variant of Raji, RJ225, is also 
  Discussion 
 78
available. RJ225 has a defect in the class II transactivator, which positively regulates the 
transcription of MHC class II genes (Accolla, 1983; Koch et al., 1988). The lack of MHC-II 
expression on RJ225 was confirmed using directly labelled antibodies and contrasted sharply 
with the Raji cell line expressing high levels of all three MHC-II isotypes. Since RJ225 does 
not express MHC-II, anti-MHC-II antibody stimulation could not increase the 
phosphorylation of ERK1/2. Crosslinking MHC-II expressed on Raji could increase ERK1/2 
phosphorylation, but interestingly only the use of anti-HLA-DP and anti-HLA-DQ antibodies 
could enhance ERK1/2 phosphorylation whereas anti-HLA-DR antibodies had no effect. 
Similar results were also seen by another group using the B cell line Ramos where anti-HLA-
DP but not anti-HLA-DR antibodies increased ERK1/2 phosphorylation (Leveille et al., 
2002). However, the Ramos B cell line does not express HLA-DQ, and thus the importance of 
this isotype in ERK1/2 MAP kinase activation was lost.        
Understanding the importance of MAP kinases in the transcription and stability of the 
proteins that make up the transcription factor, AP-1, led to additional experiments regarding 
c-Fos and AP-1 dimer formation. It is already known that ERK1/2 activity can stabilize newly 
generated c-Fos by phosphorylating the C-terminus, which increases the half-life from 30-40 
minutes to over 2 hours (Okazaki and Sagata, 1995; Chen et al., 1996). A recent study showed 
that ERK1/2 is not only important for c-Fos stabilization, but AP-1 DNA binding and AP-1 
transcriptional activity are governed by the duration of ERK1/2 activity (Chalmers et al., 
2007). By using the ERK1/2 inhibitor, U0126, and then stimulating the cells with thrombin, 
they were able to block any increase in expression of c-Fos. Similar results were seen in this 
study where U0126 blocked any increase in c-Fos expression after MHC-II stimulation. 
MHC-II stimulation augmented c-Fos expression as well as AP-1 binding activity in the same 
isotype-specific manner as MEK1/2 and ERK1/2 phosphorylation. Thus, MHC-II signaling 
shows similarities and may use a similar mechanism for stabilizing c-Fos and allowing for 
AP-1 binding as the growth factor-stimulated pathway. 
One question that arises is what causes the isotype-specific signaling differences. A structural 
study has revealed differences between the cytoplasmic tails of HLA-DP and HLA-DR 
molecules, which lead to a difference in their ability to associate with the cytoskeleton (El 
Fakhry et al., 2004). Residues at positions Gly226-His227-Ser228 of the cytoplasmic portion of 
the β chain of HLA-DR are important for cytoskeleton association as demonstrated with a 
mutant that had these amino acids substituted with alanine and could hardly associate with the 
cytoskeleton. Unlike HLA-DR, the HLA-DP β chain has Val226 and Gln227, and 
oligomerization of HLA-DP does not lead to cytoskeleton interaction. Replacing the 
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cytoplasmic HLA-DR β domain with the cytoplasmic HLA-DP β domain also prevented 
association with the cytoskeleton (El Fakhry et al., 2004). Controlling the mobility of HLA-
DR by associating with the cytoskeleton may prevent them from interacting with a signaling 
partner that ultimately activates the MAP kinases. HLA-DP is not restricted to the 
cytoskeleton after oligomerization, which may increase its accessibility so that it can interact 
with a signaling partner. 
The activation of ERK1/2 kinases with a different MHC-II ligand, superantigens, was also 
examined. Staphylococcal enterotoxin A (SEA) ligates MHC-II chains in a different manner 
to antibodies since it crosslinks MHC-II α and β chains instead of only MHC-II α or MHC-II 
β chains. The difference in ligation mode may attribute to this superantigen’s inability to 
induce apoptosis compared to the monoclonal antibody L243 (Gross et al., 2006). 
Interestingly, SEA alone and SEA further ligated with an anti-GST antibody could not 
enhance ERK1/2 phosphorylation. Using another superantigen, streptococcal pyrogenic 
exotoxin A (SPEA), which binds to the MHC-II α chain and in its dimeric form can crosslink 
MHC-II α chains, could neither alone nor with additional ligation from the anti-SPEA 
antibody, UH-1, augment ERK1/2 phosphorylation. The activation of MAP kinases after 
superantigen stimulation with T cells has been reported, but thus far there are no studies 
pertaining to MAP kinase activation after stimulating antigen presenting cells with 
superantigens (Adler et al., 1998; Torres et al., 2002). SEA and SPEA do not affect the 
classical MAP kinases in Raji B cells, but this does not rule out the possibility of 
superantigens influencing the classical MAP pathway in other antigen presenting cells such as 
monocytes. Cytokine production has been shown in bone marrow-derived macrophages and 
in the monocytic cell line THP-1 after superantigen stimulation and perhaps the classical 
MAP kinases may play a role in these cases (Homfeld et al., 1990; Trede et al., 1991; Rink et 
al., 1992, 1994; Al-Daccak et al., 1994).  
The transcription factors, NFAT and AP-1, are both activated after stimulation through MHC-
II molecules presented on B lymphocytes. NFAT activation is an isotype non-specific event 
whereas AP-1 binding activity only increased after HLA-DP and HLA-DQ ligation. NFAT is 
important for the activation and differentiation of B cells, and AP-1 is involved in growth and 
cellular proliferation. However, a different transcription factor, NF-κB, does not appear to 
play a decisive role in MHC-II signaling in this study. Since LPS stimulation could not 
properly stimulate BJAB and Raji as seen with the NF-κB EMSA, the monocytic cell line that 
responds dramatically to LPS stimulation, Mono Mac1, was chosen. An increase in NF-κB 
binding activity was seen after LPS stimulation, but not observed after stimulating Mono 
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Mac1 with anti-HLA-DR, -DP, and –DQ antibodies. There was also no increase in TNF-α 
production, and the TNF-α promoter is one of the main targets of NF-κB. Superantigen 
stimulation has been reported to activate NF-κB and AP-1, but it is difficult to rule out the 
factor of LPS contamination (Trede et al., 1993a, 1993b, 1995). The superantigens used in 
this study were completely cleared of endotoxin after using a column containing immobilized 
polymixin B. The efficacy of this endotoxin-removing step was observed by measuring TNF-
α production before and after polymixin B treatment. TNF-α production was no longer 
present after the endotoxins had been removed even though the superantigens could still bind 
to MHC-II molecules according to FACS analysis. Again, the activation of NF-κB by MHC-
II molecules cannot be completely ruled out since this may vary according to cell type or cell 
line and/or stimulation used. 
One of the major functions of B lymphocytes is the production of immunoglobulins to help 
stop and prevent the spread of infections. Antibody synthesis was analyzed in the context of 
MHC-II stimulation using superantigens and anti-MHC-II antibodies. Superantigens are 
reported to either promote a strong immunoglobulin response using low doses (0.01 ng/ml) or 
inhibit an antibody response using more mitogenic doses of superantigens (100 ng/ml) (Stohl 
et al., 1994; Stohl and Elliott, 1995; Stohl et al., 1998a). The results of this study confirm the 
latter since high doses of SEA and MAS (222 ng/ml) led to a dramatic reduction in 
immunoglobulins so that in all cases, less than 10 % of immunoglobulins was detected after 
superantigen stimulation compared to the control. The main reason for this diminishment in 
immunoglobulin production is the decrease in viable B cells. The cause for the reduction in 
viable B cells is most likely a combination of CD8+-dependent CD95-, perforin-, and TNF-
based killing as well as CD4+-dependent cytolytic CD95-based activity (Stohl et al., 1998a; 
Stohl et al., 1998b). Although superantigens are presented by antigen presenting cells and 
CD4+ T cells thus allowing for close proximity of these cells, CD8+ T cells rapidly kill (4 
hours) activated B cell targets using a perforin-based pathway as well as a CD95-based killing 
mechanism (Stohl et al., 1998b).  
Using anti-MHC-II antibodies, a decrease in immunoglobulin production was also observed, 
but not a decline in viable B cells. In fact, the number of viable B cells was generally higher 
than the IgG and negative control signifying a possible proliferation. However, the actual role 
of MHC-II molecules in triggering B cell proliferation remains controversial with conflicting 
reports (Clement et al., 1986; Cambier and Lehmann, 1989). Although the anti-MHC-II 
antibodies are replacing the initial contact of helper T cells and one might expect that contact 
with MHC-II alone could encourage antibody synthesis, this does not appear to be the case. 
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Before the B cells can differentiate into effector cells and start producing antibodies, B cells 
must undergo clonal expansion (Janeway et al., 1999). B cells are stimulated to proliferate by 
a mixture of MHC-II/TCR recognition, CD40/CD40L contact, and cytokines. Since these B 
cells are only receiving part of the signal through MHC-II, either no or only limited 
proliferation can be expected. The later stages of activating the B cells also require additional 
cytokines (e.g. IL-5 and IL-6) from armed helper T cells, which are also lacking. The 
interesting aspect is that those B cells that normally produce antibodies are inhibited from 
either synthesizing and/or secreting antibodies due to ligation of MHC-II molecules. The 
differentiation process that is triggered by pokeweed mitogen (PWM) and allows B cells to 
differentiate into plasma cells is blocked by MHC-II ligation. PWM requires the presence of 
helper T cells, and perhaps by using anti-MHC-II antibodies, the helper T cells can no longer 
properly activate the B cells (Fauci and Pratt, 1976). Earlier investigations using three 
antibodies, DA6.231, DA6.147, and DA6.164, demonstrated a reduction in PWM stimulation 
as well as the mixed lymphocyte reaction, and these responses were not due to antibody-
dependent cell-mediated cytotoxicity (ADCC) (Steel et al., 1982; Palacios et al., 1983). 
ADCC is also not a factor in this study since IgG antibodies were used that could bind to Fc 
receptors and initiate NK cell-mediated killing. In another study using purified B cells, 
ligation of HLA-DR actually enhanced expression of IgM heavy chain genes and IgM 
production, but here solid-phase antibodies were used instead of soluble antibodies and PWM 
was not applied (Tabata et al., 2000). Taken together, immunoglobulin synthesis is 
diminished after MHC-II ligation with anti-MHC-II antibodies, and this may be due to 
blocking the differentiation of B cells normally achieved by PWM stimulation. 
The signaling pathways of T cell and B cell receptors are relatively well-defined, but the 
contribution of MHC-II molecules to signaling cascades has generally been overlooked. In 
this work, the complexities of MHC-II-derived signaling was explored with regards to 
calcium mobilization, activation of the transcription factors NFAT, AP-1, and NF-κB, 
apoptosis, activation of the classical MAP kinases, and immunoglobulin synthesis. While the 
MHC-II isotype is not important for events such as calcium flux, protein tyrosine kinase 
activation, and dephosphorylation of NFAT, the isotype is significant for the activation of 
classical MAP kinases and AP-1 binding activity. Since additional signaling molecules are 
required to aid MHC-II molecules in transducing signals, understanding more about MHC-II 
signaling also relays important information about other signaling partners and how molecules 
can associate and work together. However, the presence of different molecules on different 
antigen presenting cells makes it particularly difficult to find the associated molecules that aid 
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MHC-II molecules in triggering the various signal transduction pathways (Fig. 5.1). The list 
of possible associated molecules is steadily growing and ranges from CD3 and CD28 on 
activated T cells to CD38 and CD18 on monocytes to the BCR and CD19 on B cells (Kanner 
et al., 1992; Zilber et al., 2005; Castaigne et al., 2002; Lang et al., 2001; Leveille et al., 2002).   
 
Figure 5.1 – A Summary of MHC-II-mediated Signaling Pathways Investigated in this Work. 
For the full signaling repertoire, MHC-II requires other signaling molecules and intact lipid rafts to 
activate kinases, mobilize calcium, and trigger various transcription factors such as AP-1 and NFAT. 
The blue circles indicate the signaling components newly described in this work to be involved in 
MHC-II-mediated signaling.  
 
MHC-II-mediated signaling is not only important for understanding general signaling 
mechanisms and generating a more detailed picture of what occurs at the immunological 
synapse between T cells and antigen presenting cells, but MHC-II-derived signaling has a 
powerful impact on the fate of the cell. MHC-II activation is important for regulating the 
proliferation and differentiation of B cells, aids in the maturation of dendritic cells, and is 
even capable of eliminating a wide range of antigen presenting cells such as B cells, mature 
dendritic cells, and differentiated monocytes (Charron et al., 1991; Clement et al., 1986; 
Cambier and Lehmann, 1989; Thibeault et al., 1999; Castaigne et al., 2002; Al-Daccak et al., 
2004). Some of these mechanisms such as MHC-II-mediated apoptosis have been harnessed 
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so that they are utilized in the fight against cancer (Nagy et al., 2002). Further studies that 
tackle the task of revealing the importance of NFAT in B cells will give insight into complex 
topics such as controlling antibody production and anergy, which is of great therapeutic value 
for the prevention of autoimmune diseases and transplant rejection. Future investigations will 
hopefully uncover the full potential and disclose the importance of these highly polymorphic, 
dynamic molecules.  
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VI. CONCLUSION 
MHC-II molecules are not only structures that present antigens to helper T cells, ligation of 
these molecules can induce a cascade of signaling pathways that have yet to be fully 
elucidated. MHC-II-induced signaling pathways involve a combination of different kinases 
and transcription factors that lead to different cellular responses such as proliferation, 
differentiation, and apoptosis. These signaling components were further characterized and 
new pathways were identified by activating primarily B lymphocytes expressing MHC-II 
molecules with anti-MHC-II antibodies and superantigens. 
This work shows that MHC-II-mediated calcium mobilization is an isotype-independent 
event, which leads to the dephosphorylation of NFAT. In addition, MHC-II molecules work 
in conjuction with the B cell receptor to increase NFAT activity. As opposed to calcium 
mobilization, the classical MAP kinases are activated in an isotype-specific manner where 
only ligation of HLA-DP and HLA-DQ lead to ERK1/2 and MEK1/2 phosphorylation, which 
corresponds with an increase in c-Fos protein expression and AP-1 dimer formation. MHC-II 
most likely requires one signaling partner for the activation of tyrosine kinases leading to 
calcium mobilization and NFAT dephosphorylation and a different signaling partner for 
triggering the MAP kinase cascade, whereby the restriction of HLA-DR with the cytoskeleton 
prevents HLA-DR from associating with the signaling partner.      
Two important cellular responses were also examined including apoptosis and 
immunoglobulin synthesis. Apoptosis could only be initiated by crosslinking MHC-II 
molecules with whole antibodies or Fabs crosslinked with a secondary antibody. MHC-II-
mediated cell death was found to occur in an ERK1/2-independent manner. Immunoglobulin 
synthesis was dramatically reduced after superantigen binding, and this can be explained 
through the loss of B cells by T cell activation. Anti-MHC-II antibodies can also reduce 
antibody production, but this cannot be attributed to a decrease in viable B cells. Instead, anti-
MHC-II antibodies prevent pokeweed mitogen from carrying out its function in 
differentiating naïve B cells into plasma secreting B cells. The novel discovery of the 
activation of NFAT by MHC-II may also explain the change in antibody production during 
the differentiation of B lymphocytes.  
Altogether, this work expands upon known signaling mechansisms as well as illustrates new 
signaling pathways generated by ligating MHC-II molecules. Extending our understanding on 
MHC-II-mediated signaling can help provide new therapeutic tools for the fields of cancer, 
autoimmunity, and transplantation therapy.  
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VIII. LIST OF ABBREVIATIONS 
ADCC antibody-dependent cell-mediated cytotoxicity 
AP-1 activator protein 1 
APC antigen presenting cells 
APS ammonium persulfate 
BCR B cell receptor 
BSA bovine serum albumin 
CIITA class II transactivator 
CD clusters of differentiation 
CsA cyclosporine A 
DAG diacylglycerol 
DC dendritic cell 
DNA deoxyribonucleic acid 
dNTP deoxyribonucleotide triphosphate 
DTT dithiothreitol 
EDTA ethylene diamine tetra acetic acid 
ELISA enzyme-linked immunosorbent assay 
EMSA electrophoretic mobility shift assay 
ERK extracellular signal-regulated kinase 
Fab fragment (antigen-binding) 
FACS fluorescence-activated cell sorter 
Fc fragment (crystallized) 
FCS fetal calf serum 
FITC florescein isothiocyanate 
FSC forward scatter 
GEM glycolipid-enriched membrane microdomains  
GFP  green fluorescent protein 
GPI glycosylphosphatidylinositol 
GST glutathione-S-transferase 
HLA human leukocyte antigen 
Ig immunoglobulin 
IL interleukin  
IPTG isopropyl-beta-D-thiogalactopyranoside 
JNK c-Jun N-terminal kinase 
  List of Abbreviations 
 99
LAG-3 lymphocyte-activating gene 3 
LB Luria broth 
LFA lymphocyte function-associated antigen 
LPS lipopolysaccharide 
MAPK mitogen-activated protein kinase 
MAS Mycoplasma arthritidis-derived superantigen 
MβCD methyl-β-cyclodextrin 
MEK MAP/Erk kinase 
MHC major histocompatibility complex 
NEAA non-essential amino acids 
NFAT nuclear factor of activated T cells 
NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells 
NLS nuclear localization signal 
OD optical density 
PAGE polyacrylamide gel electrophoresis 
PBMC peripheral blood mononuclear cells 
PBS phosphate buffered saline 
PE phycoerythrin 
PHA phytohemagglutinin 
PI propidium iodide 
PI3 inositol triphosphate 
PIP2 phosphatidylinositol bisphosphate 
PKC protein kinase C 
PLC phospholipase C 
PTK protein tyrosine kinase 
PWM pokeweed mitogen 
RTK  receptor tyrosine kinase 
SD standard deviation 
SDS sodium dodecyl sulfate 
SE staphylococcal enterotoxin 
SEM standard error of mean 
shRNA short hairpin ribonucleic acid 
SPE streptococcal pyrogenic exotoxin 
SSC side scatter 
  List of Abbreviations 
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TCR T cell receptor 
TD thymus-dependent  
TEMED N,N,N’,N’-tetramethylethylenediamine 
TI thymus-independent 
TNF tumor necrosis factor  
Tris tris-(hydroxymethyl)-aminomethane 
TSST-1 toxic shock syndrome toxin-1 
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